

AJ
Au 94/15753
AY

AUSTRALIA

PATENTS ACT 1990

PATENT REQUEST : STANDARD PATENT

I/We being the person(s) identified below as the Applicant(s), request the grant of a patent to the person(s) identified below as the Nominated Person(s), for an invention described in the accompanying standard complete specification.

Full application details follow:

[71/70] Applicant(s)/Nominated Person(s):

Sanofi

of

32-34, rue Marbeuf, Paris, 75008, France

INFORMATION SERVICES
DEPT.

OCT 12 1995

[54] Invention Title:

Substituted 1-naphthyl-3-pyrazolecarboxamides which are active on neurotensin, their preparation and pharmaceutical compositions containing them

[72] Name(s) of actual inventor(s):

Bernard LABEEUW
Danielle GULLY
Francis JEANJEAN
Jean-Charles MOLIMARD
Robert BOIGEGRAIN

[74] Address for service in Australia:

DAVIES COLLISON CAVE, Patent Attorneys, 1 Little Collins Street,
Melbourne, Victoria, Australia. Attorney Code: DM

Basic Convention Application(s) Details:

[31] Application Number	[33] Country	Code	[32] Date of Application
93 12136	France	FR	12 October 1993

DATED this TWELFTH day of OCTOBER 1994

Keith Walsh

.....
a member of the firm of
DAVIES COLLISON CAVE for
and on behalf of the
applicant(s)


AUSTRALIA
PATENTS ACT 1990
NOTICE OF ENTITLEMENT

We, Sanofi, the applicant/Nominated Person named in the accompanying Patent Request state the following:-

The Nominated Person is entitled to the grant of the patent because the Nominated Person would, on the grant of a patent for the invention to the inventors, be entitled to have the patent assigned to the Nominated Person.

The Nominated Person is entitled to claim priority from the basic application listed on the patent request because the Nominated Person made the basic application, and because that application was the first application made in a Convention country in respect of the invention.

DATED this TWELFTH day of OCTOBER 1994



a member of the firm of
DAVIES COLLISON
CAVE for and on behalf
of the applicant(s)

(DCC ref: 1697716)




AU9475753

(12) PATENT ABSTRACT (11) Document No. AU-A-75753/94
(19) AUSTRALIAN PATENT OFFICE

- (54) Title
SUBSTITUTED 1-NAPHTHYL-3-PYRAZOLECARBOXAMIDES WHICH ARE ACTIVE ON
NEUROTENSIN, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING
THEM
- (51)⁵ International Patent Classification(s)
C07D 231/14 A61K 031/47 C07D 401/10 A61K 031/415
- (21) Application No. : 75753/94 (22) Application Date : 12.10.94
- (30) Priority Data
- (31) Number (32) Date (33) Country
93 12136 12.10.93 FR FRANCE
- (43) Publication Date : 04.05.95
- (71) Applicant(s)
SANOFI
- (72) Inventor(s)
BERNARD LABEEUW; DANIELLE GULLY; FRANCIS JEANJEAN; JEAN-CHARLES MOLIMARD;
ROBERT BOIGEGRAIN
- (74) Attorney or Agent
DAVIES COLLISON CAVE, 1 Little Collins Street, MELBOURNE VIC 3000
- (57) Claim

1. A compound of formula:



in which:

- R represents a group chosen from:

-CN, $-\text{C}(\text{NH}_2) = \text{N}-\text{OH}$, $-\text{C}(\text{NR}_4\text{R}_5) = \text{NR}_6$,

$-\text{CONR}_1\text{R}_2$, $-\text{CON}(\text{R}_7)(\text{CH}_2)_p\text{NR}_1\text{R}_2$,

$-\text{CON}(\text{R}_7)(\text{CH}_2)_q\text{CN}$, $-\text{CON}(\text{R}_7)(\text{CH}_2)_q\text{C}(\text{NR}_{14}\text{R}_{15}) = \text{N}-\text{R}_{16}$,

$-\text{CH}_2\text{CN}$, $-\text{CH}_2\text{CONR}_1\text{R}_2$, $-\text{CH}_2\text{CON}(\text{R}_7)(\text{CH}_2)_p\text{NR}_1\text{R}_2$,

$-\text{CH}_2\text{CON}(\text{R}_7)(\text{CH}_2)_q\text{CN}$, $-\text{CH}_2\text{COOR}_7$,

$-\text{O}(\text{CH}_2)_n\text{NR}_1\text{R}_2$, $-\text{O}(\text{CH}_2)_n\text{CONR}_1\text{R}_2$,

$-\text{O}(\text{CH}_2)_n\text{COOR}_7$, $-\text{O}(\text{CH}_2)_n\text{SO}_2\text{NR}_1\text{R}_2$,

$-\text{N}(\text{R}_7)\text{COR}_3$, $-\text{N}(\text{R}_7)\text{CO}(\text{CH}_2)_n\text{NR}_1\text{R}_2$,

$-\text{N}(\text{R}_7)\text{CO}(\text{CH}_2)_n\text{NHCOR}_3$, $-\text{N}(\text{R}_7)\text{SO}_2\text{R}_8$,

$-\text{N}(\text{R}_7)\text{CONR}_9\text{R}_{10}$, $-\text{CH}_2\text{N}(\text{R}_7)\text{COR}_3$,

$-\text{CH}_2\text{N}(\text{R}_7)\text{SO}_2\text{R}_8$, $-\text{CH}_2\text{CH}_2\text{NR}_{11}\text{R}_{12}$,

$-\text{CH}_2\text{CH}_2\text{N}(\text{R}_7)\text{COR}_3$, $-\text{CH}_2\text{CH}_2\text{N}(\text{R}_7)\text{SO}_2\text{R}_8$,

$-\text{SO}_2\text{NR}_1\text{R}_2$, $-\text{SO}_2\text{N}(\text{R}_7)(\text{CH}_2)_n\text{NR}_1\text{R}_2$,

$-\text{CH}_2\text{CON}(\text{R}_7)(\text{CH}_2)_q\text{C}(\text{NR}_{14}\text{R}_{15}) = \text{NR}_{16}$

$-\text{N}(\text{R}_7)\text{CO}(\text{CH}_2)_q\text{CN}$, $-\text{N}(\text{R}_7)\text{CO}(\text{CH}_2)_q\text{C}(\text{NR}_{14}\text{R}_{15}) = \text{NR}_{16}$,

$-\text{SO}_2\text{N}(\text{R}_7)(\text{CH}_2)_q\text{CN}$, $-\text{SO}_2\text{N}(\text{R}_7)(\text{CH}_2)_q\text{C}(\text{NR}_{14}\text{R}_{15}) = \text{NR}_{16}$;

- or alternatively R, linked with the carbon atom at position 5 of the naphthyl radical, forms a group:

-CON(R₁₃)CO-

- p = 2 to 6;
- n = 1 to 6;
- q = 1 to 5;
- R₁ and R₂ each independently represent a hydrogen or a (C₁-C₄) alkyl; or R₁ and R₂, together with the nitrogen atom to which they are attached, represent a heterocycle chosen from: pyrrolidine, piperidine, piperazine substituted at position 4 with R₇, morpholine or thiomorpholine;
- R₃ represents hydrogen; a (C₁-C₈) alkyl; a (C₃-C₈) cycloalkyl; a phenyl; a piperidyl;
- R₄ and R₅ each independently represent a hydrogen or a (C₁-C₄) alkyl;
- R₆ represents a (C₁-C₄) alkyl;
- R₇ represents a hydrogen or a (C₁-C₄) alkyl;
- R₈ represents a (C₁-C₄) alkyl;
- R₉ and R₁₀ each independently represent a hydrogen or a (C₁-C₄) alkyl; R₁₀ can, furthermore, represent a group -(CH₂)_nNR₁R₂;
- or R₉ and R₁₀, together with the nitrogen atom to which they are attached, represent a heterocycle chosen from: pyrrolidine, piperidine, piperazine substituted at position 4 with R₇, morpholine or thiomorpholine;
- R₁₁ and R₁₂ each independently represent a hydrogen or a (C₁-C₄) alkyl; or R₁₁ and R₁₂, together with the nitrogen atom to which they are attached, represent pyrrolidine or piperidine;
- R₁₃ represents a hydrogen; a group -(CH₂)_nNR₁R₂; a group -NHCOR₃;
- R₁₄ and R₁₅ each independently represent a hydrogen or a (C₁-C₄) alkyl;
- R₁₆ represents a hydrogen; R₁₆ can, furthermore, represent a (C₁-C₄) alkyl when R₁₄ represents a hydrogen and R₁₅ represents a (C₁-C₄) alkyl;
- or R₁₄ and R₁₆ together represent an ethylene group or a


(11) 75753/94

4

trimethylene group and R_{15} represents a hydrogen or a (C_1 - C_4) alkyl;


- T represents hydrogen; a (C_1 - C_4) alkyl; an allyl; a (C_3 - C_8) cycloalkyl; a (C_3 - C_8) cycloalkylmethyl; a methoxyethyl;

- the group $-NH-AA(OH)$ represents the residue of an amino acid:



where X is hydrogen and X' is hydrogen, a (C_1 - C_5) alkyl or a non-aromatic C_3 - C_{15} carbocyclic radical; or alternatively X and X' , together with the carbon atom to which they are attached, form a non-aromatic C_3 - C_{15} carbocycle; and its salts.

3. A compound of formula:




in which

- R_a represents an N -[3-(N',N' -dimethylamino)propyl]-aminocarbonyl or N -[2-(N',N' -dimethylamino)ethyl]amino-


carbonyl group;
and its salts.

4. A process for the preparation of a compound according to Claim 1 of formula I and its salts, characterized in that:

1) a functional derivative of a 1-naphthyl-3-pyrazolecarboxylic acid of formula:



in which T and R have the meanings given above for the compound of formula I and R' represents a precursor of R chosen from nitro, amino, hydroxyl, sulfo, chloro-sulphonyl and carboxyl groups, is treated with an amino acid, optionally protected by protective groups which are customary in peptide synthesis, of formula:




in which $-\text{NH}-\text{AA}(\text{OH})$ is as defined above for the compound of formula I;

(11) 75753/94

6

2) where appropriate, the compound thereby obtained, of formula:



is subjected to a subsequent treatment suitable for converting the substituent R', a precursor of R, to the substituent R;

3) if necessary, the compound thereby obtained in step 1) or in step 2) is deprotected to yield the corresponding free acid of formula I;

4) where appropriate, a salt is prepared of the compound I thereby obtained.

8. Pharmaceutical composition containing as active principle a compound of formula I according to any one of Claims 1 to 3 or one of its possible pharmaceutically acceptable salts.

AUSTRALIA
PATENTS ACT 1990
COMPLETE SPECIFICATION

NAME OF APPLICANT(S):

Sanofi

ADDRESS FOR SERVICE:

DAVIES COLLISON CAVE
Patent Attorneys
1 Little Collins Street, Melbourne, 3000.

INVENTION TITLE:

Substituted 1-naphthyl-3-pyrazolecarboxamides which are active on neurotensin,
their preparation and pharmaceutical compositions containing them

The following statement is a full description of this invention, including the best method
of performing it known to me/us:-

The present invention relates to new substituted 1-naphthyl-3-pyrazolecarboxamides having a great affinity for the human neurotensin receptor, to a process for preparing them and to pharmaceutical compositions containing them as active principles.


The first synthetic non-peptide potential medicinal products capable of binding to neurotensin receptors have been described in EP-0,477,049. They are amides of 3-pyrazolecarboxylic acid, variously substituted with amino acids, which displace iodinated neurotensin from its receptor, at doses of less than one micromole, on guinea pig brain membranes. This series led to the development of a compound, 2-[1-(7-chloro-4-quinolyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino]-2-adamantanecarboxylic acid, SR 48692, endowed with potent and selective neurotensin-antagonist activity (D. Gully et al., Proc. Natl. Acad. Sci. USA, 1993, 90, 65-69).

The feature of the series of products described in EP-0,477,049 is the presence at position 1 of the pyrazole ring of, in particular, a phenyl, naphthyl or 4-quinolyl group, substituted or unsubstituted. More especially, SR 48692 possesses a 7-chloro-4-quinolyl group in position 1 of the pyrazole. The products described in this document having a 1-naphthyl or 4-chloro-1-naphthyl group in position 1 of the pyrazole ring have an extremely high affinity for the guinea pig neurotensin receptor, since their IC₅₀ is of the order of 1 to 10 nanomoles, whereas their affinity for the human receptor is lower since their IC₅₀ is from 10 to 100 nmol.

It has now been found that, by substituting position 4 of the naphthyl group of 1-naphthyl-3-pyrazolecarboxamide compounds with particular groups, the affinity for the neurotensin receptor is increased, and more especially the affinity for the human neurotensin receptor is increased.

Thus, the present invention relates, according to one of its aspects, to new substituted 1-naphthyl-3-

pyrazolecarboxamides of formula:



in which:

- R represents a group chosen from:

-CN, $-C(NH_2)=N-OH$, $-C(NR_4R_5)=NR_6$,

-CONR₁R₂, $-CON(R_7)(CH_2)_pNR_1R_2$,

$-CON(R_7)(CH_2)_qCN$, $-CON(R_7)(CH_2)_qC(NR_{14}R_{15})=N-R_{16}$,

$-CH_2CN$, $-CH_2CONR_1R_2$, $-CH_2CON(R_7)(CH_2)_pNR_1R_2$,

$-CH_2CON(R_7)(CH_2)_qCN$, $-CH_2COOR_7$,

$-O(CH_2)_nNR_1R_2$, $-O(CH_2)_nCONR_1R_2$,

$-O(CH_2)_nCOOR_7$, $-O(CH_2)_nSO_2NR_1R_2$,

$-N(R_7)COR_3$, $-N(R_7)CO(CH_2)_nNR_1R_2$,

$-N(R_7)CO(CH_2)_nNHCOR_3$, $-N(R_7)SO_2R_8$,

$-N(R_7)CONR_9R_{10}$, $-CH_2N(R_7)COR_3$,

$-CH_2N(R_7)SO_2R_8$, $-CH_2CH_2NR_{11}R_{12}$,

$-CH_2CH_2N(R_7)COR_3$, $-CH_2CH_2N(R_7)SO_2R_8$,

$-SO_2NR_1R_2$, $-SO_2N(R_7)(CH_2)_nNR_1R_2$,

$-CH_2CON(R_7)(CH_2)_qC(NR_{14}R_{15})=NR_{16}$

$-N(R_7)CO(CH_2)_qCN$, $-N(R_7)CO(CH_2)_qC(NR_{14}R_{15})=NR_{16}$,

-SO₂N(R₇)(CH₂)_qCN, -SO₂N(R₇)(CH₂)_qC(NR₁₄R₁₅) = NR₁₆ ;
 - or alternatively R, linked with the carbon atom at position 5 of the naphthyl radical, forms a group:

5

-CON(R₁₃)CO-

- p = 2 to 6;

- n = 1 to 6;

- q = 1 to 5;

10 - R₁ and R₂ each independently represent a hydrogen or a (C₁-C₄) alkyl; or R₁ and R₂, together with the nitrogen atom to which they are attached, represent a heterocycle chosen from: pyrrolidine, piperidine, piperazine substituted at position 4 with R₇, morpholine or thiomorpholine;

15 - R₃ represents hydrogen; a (C₁-C₈) alkyl; a (C₃-C₈) cycloalkyl; a phenyl; a piperidyl;

- R₄ and R₅ each independently represent a hydrogen or a (C₁-C₄) alkyl;

20 - R₆ represents a (C₁-C₄) alkyl;

- R₇ represents a hydrogen or a (C₁-C₄) alkyl;

- R₈ represents a (C₁-C₄) alkyl;

- R₉ and R₁₀ each independently represent a hydrogen or a (C₁-C₄) alkyl; R₁₀ can, furthermore, represent a group -(CH₂)_nNR₁R₂;

25 - or R₉ and R₁₀, together with the nitrogen atom to which they are attached, represent a heterocycle chosen from: pyrrolidine, piperidine, piperazine substituted at position 4 with R₇, morpholine or thiomorpholine;

30 - R₁₁ and R₁₂ each independently represent a hydrogen or a (C₁-C₄) alkyl; or R₁₁ and R₁₂, together with the nitrogen atom to which they are attached, represent pyrrolidine or piperidine;

- R₁₃ represents a hydrogen; a group -(CH₂)_nNR₁R₂; a group -NHCOR₃;

35 - R₁₄ and R₁₅ each independently represent a hydrogen or a (C₁-C₄) alkyl;

- R₁₆ represents a hydrogen; R₁₆ can, furthermore, represent a (C₁-C₄) alkyl when R₁₄ represents a


hydrogen and R₁₅ represents a (C₁-C₄) alkyl;

- or R₁₄ and R₁₆ together represent an ethylene group or a trimethylene group and R₁₅ represents a hydrogen or a (C₁-C₄) alkyl;

5 - T represents hydrogen; a (C₁-C₄) alkyl; an allyl; a (C₃-C₈) cycloalkyl; a (C₃-C₈) cycloalkylmethyl; a methoxyethyl;

- the group -NH-AA(OH) represents the residue of an amino acid;

10



15 where X is hydrogen and X' is hydrogen, a (C₁-C₅) alkyl or a non-aromatic C₃-C₁₅ carbocyclic radical; or alternatively X and X', together with the carbon atom to which they are attached, form a non-aromatic C₃-C₁₅ carbocycle;

and their salts.

20 Advantageously the invention relates to the compounds of formula I in which:

- R represents a group chosen from:


-CN, -C(NH₂)=N-OH, -CONR₁R₂, -CON(R₇)(CH₂)_pNR₁R₂,

-O(CH₂)_nNR₁R₂, -O(CH₂)_nCONR₁R₂, -O(CH₂)_nCOOR₇,

-O(CH₂)_nSO₂NR₁R₂, -NHCOR₃, -NHCO(CH₂)_nNR₁R₂,

-CH₂CONR₁R₂, -CH₂CON(R₇)(CH₂)_pNR₁R₂, -CH₂COOR₇,

-CH₂NHCOR₃, -SO₂NR₁R₂, -NHSO₂R₈,

-SO₂N(R₇)(CH₂)_aNR₁R₂, -SO₂-N  NR₇


- p = 2 to 6;

25 - n = 1 to 6;

- R₁ and R₂ each independently represent a hydrogen or

a (C₁-C₄) alkyl; or R₁ and R₂, together with the nitrogen atom to which they are attached, represent a heterocycle chosen from pyrrolidine, piperidine, piperazine, morpholine or thiomorpholine;

- 5 - R₃ represents hydrogen; a (C₁-C₈) alkyl, a (C₃-C₈) cycloalkyl, a phenyl;
- R₇ represents a hydrogen or a (C₁-C₄) alkyl;
- R₈ represents a (C₁-C₄) alkyl;
- T represents hydrogen, a C₁-C₄ alkyl, an allyl, a
- 10 C₃-C₈ cycloalkyl, a (C₃-C₈) cycloalkylmethyl, a methoxyethyl,
- the group -NH-AA(OH) represents the residue of an amino acid:



15

where X is hydrogen and X' is hydrogen, a C₁-C₅ alkyl or a non-aromatic C₃-C₁₅ carbocyclic radical, or alternatively X and X', together with the carbon atom to which they are attached, form a non-aromatic C₃-C₁₅ carbocycle;

20 and their salts.

According to the present invention, C₁-C₄ or, respectively, C₁-C₅ or, respectively, C₁-C₈ alkyl is understood to mean an unbranched or branched C₁-C₄ or, respectively, C₁-C₅ or, respectively, C₁-C₈ alkyl.

25

Non-aromatic C₃-C₁₅ carbocyclic radicals comprise saturated or unsaturated, fused or bridged mono- or polycyclic radicals, optionally terpenic. These radicals are optionally mono- or polysubstituted with a C₁-C₄ alkyl.

30

Monocyclic radicals include C₃-C₁₅ cycloalkyls, for example cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclododecyl.

35 In the above residue of the amino acid, when X and X', together with the carbon atom to which they are attached, form a non-aromatic C₃-C₁₅ carbocycle, the said carbocycle is as defined for the corresponding

radicals above.

Among polycyclic non-aromatic carbocycles, adamantane is the preferred member, it being possible for the corresponding radical to be 1-adamantyl when X is hydrogen or 2-adamantylidene when X and X', together with the carbon atom to which they are attached, form a carbocycle.

Among monocyclic non-aromatic carbocycles, cyclopentane and cyclohexane are especially preferred.


10 In the formula I, R advantageously represents a group chosen from: $-\text{CONR}_1\text{R}_2$, $-\text{CH}_2\text{CONR}_1\text{R}_2$ and $-\text{O}(\text{CH}_2)_n\text{CONR}_1\text{R}_2$, the substituents R_1 and R_2 preferably being hydrogen and n preferably being 1; $-\text{N}(\text{R}_7)\text{COR}_3$, the substituent R_3 being, in particular, a ($\text{C}_1\text{-C}_8$) alkyl, preferably a methyl, and R_7 preferably being hydrogen; $-\text{CON}(\text{R}_7)(\text{CH}_2)_p\text{NR}_1\text{R}_2$, the substituent R_7 preferably being a hydrogen or a methyl, R_1 and R_2 both preferably being methyl and p preferably being 2, 3 or 4; and $-\text{SO}_2\text{N}(\text{R}_7)(\text{CH}_2)_n\text{NR}_1\text{R}_2$, the substituent R_7 preferably being hydrogen or methyl, R_1 and R_2 both preferably being methyl and n preferably being 2, 3 or 4 ; and $-\text{CON}(\text{R}_7)(\text{CH}_2)_q\text{C}(\text{NR}_{14}\text{R}_{15}) = \text{NR}_{16}$, the substituent R_7 preferably being hydrogen or methyl, R_{14} and R_{16} both preferably being methyl, R_{15} preferably being hydrogen and q preferably being 2 or 3. Still more advantageously, at the same time, in the formula I, T represents hydrogen or a methyl or cyclopropylmethyl group. Preferably, at the same time, in the formula I, the group AA(OH) represents a 2-carboxy-2-adamantyl or α -carboxycyclohexylmethyl radical, these two radicals representing, with the adjacent NH group, the N-terminal residues of 2-amino-2-adamantane-carboxylic acid and α -aminocyclohexaneacetic acid (cyclohexylglycine), respectively.

35 Preferred substituted 1-naphthyl-3-pyrazole-carboxamides according to the present invention are those of formula I in which:

- R represents an aminocarbonyl; aminocarbonylmethyl; acetamido; $\text{N}-[3-(\text{N}', \text{N}'\text{-dimethylamino})\text{propyl}]\text{amino-}$

sulphonyl; N-methyl-N-[3-(N',N'-dimethylamino)propyl]-
 aminosulphonyl; carbamoylmethoxy; N-[3-(N',N'-di-
 methylamino)propyl]aminocarbonyl; N-[2-(N',N'-dimethyl-
 amino)ethyl]aminocarbonyl; N-methyl-N-[3-(N',N'-di-
 methylamino)propyl]aminocarbonyl; N-methyl-N-[2-(N',N'-
 dimethylamino)ethyl]aminocarbonyl group ; N-methyl-N-
 [2-N¹-methyl-N²-methylamidino)ethyl]carbamoyl ;
 - T represents a methyl or cyclopropylmethyl group; and
 - the group -NH-AA-(OH) represents the residue of 2-
 amino-2-adamantanecarboxylic or (S)-α-aminocyclohexane-
 acetic acid;
 and their salts.

Preference attaches most especially to the
 compounds of formula:



in which

- R_a represents an N-[3-(N',N'-dimethylamino)propyl]-
 aminocarbonyl or N-[2-(N',N'-dimethylamino)ethyl]amino-
 carbonyl group;
 and their salts.

The salts of the invention compounds are those
 with alkali metals, preferably sodium or potassium, and
 alkaline-earth metals, preferably calcium, and with
 organic bases such as diethylamine, tromethamine,
 meglumine (N-methyl-D-glucamine), lysine, arginine,
 histidine or diethanolamine.

The salts of the compounds of formula I
 according to the present invention also comprise those


with inorganic or organic acids which permit an appropriate separation or crystallization of the compounds of formula I, such as picric acid, oxalic acid or an optically active acid, for example a mandelic acid or a camphorsulphonic acid, and those which form pharmaceutically acceptable salts such as the hydrochloride, hydrogen sulphate, dihydrogen phosphate, methane-sulphonate, maleate, fumarate, 2-naphthalenesulphonate and isethionate.

When the compounds I include an asymmetric carbon, the enantiomers form part of the invention.

When the group $-NH(AA)OH$ represents the residue of a cycloaliphatic amino acid, the amino or aminomethyl groups can be in the endo position or in the exo position with respect to the ring-system; in both cases, the compounds of formula I form part of the invention.

According to another of its aspects, the present invention relates to a process for the preparation of the substituted 1-naphthyl-3-pyrazolecarboxamides of formula I and their salts, characterized in that:


1) a functional derivative of a 1-naphthyl-3-pyrazolecarboxylic acid of formula:



in which T and R have the meanings given above for the compound of formula I and R' represents a precursor of R chosen from nitro, amino, hydroxyl, sulpho, chloro-sulphonyl and carboxyl groups, is treated with an amino acid, optionally protected by protective groups which are customary in peptide synthesis, of formula:

in which -NH-AA(OH) is as defined above for the compound of formula I;

- 5 2) where appropriate, the compound thereby obtained, of formula:



- 10 is subjected to a subsequent treatment suitable for converting the substituent R', a precursor of R, to the substituent R;

- 3) if necessary, the compound thereby obtained in step 1) or in step 2) is deprotected to yield the
15 corresponding free acid of formula I;

- 4) where appropriate, a salt is prepared of the compound I thereby obtained.

- As a functional derivative of the substituted 1-naphthyl-3-pyrazolecarboxylic acid of formula II or
20 II', it is possible to use the acid chloride, the anhydride, a mixed anhydride, a C₁-C₄ alkyl ester, an activated ester, for example the p-nitrophenyl ester, or the free acid appropriately activated, for example with N,N-dicyclohexylcarbodiimide or with benzotriazol-
25 1-yloxytris(dimethylamino)phosphonium hexafluoro-phosphate (BOP).

- The amino acids of formula III may be used either as they are, or after prior protection of the carboxyl group with protective groups which are
30 customary in peptide synthesis, as described, for example, in Protective Groups in Organic Chemistry, Ed. J.F.W. McOmie, Plenum Press, 1973, page 183, or in Protective Groups in Organic Synthesis, II Ed. J.F.W.

Greene and P.G.M. Wuts, John Wiley & Sons, 1991, page 224.

For this protection, the carboxyl group of the amino acid III may be quite simply esterified, for example in the form of the methyl, isobutyl or tert-butyl ester, the esterifying group then being removed by saponification or reduction. Protection by esterification can be used only when the group R or R' does not contain, for its part also, either an ester group which must be preserved, as in the case where, for example, R might represent a group $O(CH_2)_nCOOR_7$ or CH_2COOR_7 with R_7 = alkyl, or, in any case, a group liable to be effected during the unblocking of the ester group. Protection of the carboxyl group of the amino acid III may also be performed by silylation, for example with bis(trimethylsilyl)acetamide, it being possible for the said protection to be performed *in situ*. The silyl ester of the compound I is then readily decomposed during the isolation of the final product by simple acidification.

Thus, in step 1) of the process, the chloride of a 1-naphthyl-3-pyrazolecarboxylic acid, obtained by reacting thionyl chloride or oxalyl chloride with an acid of formula II or II', may be reacted with an amino acid of formula III, in a solvent such as acetonitrile, THF, DMF or DCM, under an inert atmosphere, at room temperature, for a time between a few hours and a few days, in the presence of a base such as pyridine, sodium hydroxide or triethylamine.

A variant of step 1) consists in preparing the acid chloride or the mixed anhydride of a 1-naphthyl-3-pyrazolecarboxylic acid by reacting isobutyl or ethyl chloroformate with an acid of formula II or II', in the presence of a base such as triethylamine, and in reacting it with an N,O-bis(trimethylsilyl) derivative of an amino acid of formula III, obtained by reacting bis(trimethylsilyl)acetamide or 1,3-bis(trimethylsilyl)urea with an amino acid of formula III, in solvents such as acetonitrile or DCM, under an inert

atmosphere, at room temperature, for a time between 1 day and a few days.


Another variant to the procedure of step 1) consists in reacting the mixed anhydride of a 1-naphthyl-3-pyrazolecarboxylic acid of formula II or II' with an amino acid of formula III, in a solvent such as DCM, under an inert atmosphere, at room temperature, for a time between 1 day and a few days, in the presence of a base such as triethylamine.

When the compound of formula I possesses a basic function and is obtained in the form of a free base, salification is performed by treatment with the chosen acid in an organic solvent. By treatment of the free base, dissolved, for example, in an alcohol such as methanol, with a solution of the chosen acid in the same solvent or another solvent such as ethyl ether, the corresponding salt is obtained, which salt is isolated according to standard techniques. Thus, for example, the hydrochloride, hydrobromide, sulphate, hydrogen sulphate, dihydrogen phosphate, methanesulphonate, methyl sulphate, oxalate, maleate, fumarate, 2-naphthalenesulphonate or isethionate is prepared.

When the compound of formula I possesses a basic function and is isolated in the form of one of its salts, for example the hydrochloride or oxalate, the free base may be prepared by neutralization of the said salt with an inorganic or organic base such as sodium hydroxide or triethylamine, or with an alkali metal carbonate or bicarbonate such as sodium or potassium carbonate or bicarbonate.

When the product of formula I is obtained in acid form, it may be converted to a metal salt, in particular an alkali metal salt such as the sodium salt or an alkaline-earth metal salt such as the calcium salt, according to standard processes.

The substituted 1-naphthyl-3-pyrazolecarboxylic acids of formula:




in which T and R have the definitions given above for the compounds I and R' represents a precursor of R
 5 chosen from nitro, amino, hydroxyl, sulpho, chloro-
 sulphonyl and carboxyl groups, as well as their
 functional derivatives of the acid function, are key
 intermediates in the preparation of the compounds of
 formula I. When R' is other than carboxyl, the
 10 compounds of formulae II and II' are new and they
 constitute a further aspect of the present invention.

The acids of formulae II and II', the chlorides
 of the acids of formulae II and II', the C₁-C₄ alkyl
 esters of the acids of formulae II and II', which can
 15 also be precursors of the said acids (in particular the
 methyl, ethyl and t-butyl esters), and the mixed
 anhydride of the acids of formulae II and II' with
 isobutyl or ethyl chloroformate are especially
 preferred intermediate products.

20 The process for preparing the compounds II or
 II' via the esters IIa or II'a is represented by the
 following scheme:

- 13 -
SCHEME 1



In the first step a), a strong base such as sodium methylate is reacted with a ketone of formula 1 in which T is as defined above, and an equimolar amount of ethyl oxalate in an alkanol such as, for example, methanol is then reacted (step b)) according to L. Claisen, Ber., 1909, 42, 59. After precipitation in an ether such as ethyl ether or isopropyl ether, the sodium enolates 2 are separated by filtration. It is also possible to prepare a lithium enolate according to W.V. Murray et al., J. Heterocyclic Chem., 1989, 26, 1389.

The metal enolate 2 thus prepared and an excess of naphthylhydrazine derivative 3, or of a salt of the latter, are then heated to reflux of acetic acid (step c)) to obtain the esters IIa or II'a.

5 By saponification of the esters IIa or II'a by the action of an alkaline agent such as, for example, potassium hydroxide, sodium hydroxide or lithium hydroxide, followed by acidification, the acids II or II' are obtained (step d)).

10 In a particular case, a compound of formula II in which R, linked with the carbon atom at position 5 of the naphthyl radical, forms a group $-\text{CO}-\text{N}(\text{R}_{13})\text{CO}-$ with $\text{R}_{13} = -\text{NHCOR}_3$, is prepared using the process illustrated in Scheme 2 below:


10
10
10
10
10

10
10
10
10
10

10
10
10
10
10


10
10
10
10
10

- 15 -
SCHEME 2



In the first step a'), the potassium salt of 4-sulpho-1,8-naphthalic anhydride is reacted with hydrazine monohydrate by heating to a temperature of 120°C for 36 hours. After precipitation in water, the compound 5 is separated by filtration. Reaction of the hydrazine 5 with the metal enolate 2 (step b') according to the process described in step c) of Scheme 1 enables the esters II"a to be obtained. By saponification of the esters II"a (step c') according to the process described in step d) of Scheme 1, the acids II" are obtained. By reaction of the acids II" with suitable acid chlorides or anhydrides, the expected compounds II are obtained.

Some of the compounds of formula 3 are new and are a further object of the present invention. Thus, the compounds of formula :




in which :

R_y represents a cyano or a carboxymethyl group and their salts are novel and within the scope of the present invention.

The naphthylhydrazine derivatives (3) bearing a substituent R or a substituent R' may be prepared by diazotization of the corresponding naphthylamine in the presence of sodium nitrite, followed by reduction of the diazonium salt, for example by the action of stannous chloride. The substituted naphthylamines are known or prepared by known methods.

The naphthylhydrazine derivatives in which R, linked with the carbon atom at position 5 of the naphthyl radical, forms a group -CON(R₁₃)CO-, with R₁₃ = H or -(CH₂)_nNR₁R₂, are prepared using the process illustrated in Scheme 3 below:

- 17 -
SCHEME 3



Reaction of the compound 4 with an amine of
 5 formula H_2NR_{13} in which R_{13} is hydrogen or a group
 $-(CH_2)_nNR_1R_2$ enables the compounds 6 to be obtained
 (step a''). By heating the compounds 6 with hydrazine
 monohydrate in aqueous solution, the expected
 hydrazines 3 are obtained (step b'').

10 The conversion of a compound of formula I' or,
 respectively, of formula II' or formula II'a in which
 the naphthyl group is substituted with R' to a compound
 of formula I or, respectively, of formula II or formula
 15 IIa in which the naphthyl group is substituted with R
 is performed by standard methods well known to a person
 skilled in the art.

For example, when $R' = SO_3H$, a compound II'a in
 which $R' = SO_2Cl$ is prepared, and is then converted to
 another compound IIa, in which R is an optionally
 20 substituted aminosulphonyl group, by the action of a
 suitable amine of formula NHR_1R_2 , $HN(R_7)(CH_2)_nNR_1R_2$ or
 $HN(R_7)(CH_2)_qCN$ in which R_1 , R_2 , R_7 , n and q have the

definitions given above for the compound of formula I.

The compounds of formula IIa in which R represents a carboxymethyl group enable compounds of formula IIa in which R represents a group $-\text{CH}_2\text{CONR}_1\text{R}_2$ or, respectively, a group $-\text{CH}_2\text{CON}(\text{R}_7)(\text{CH}_2)_p\text{NR}_1\text{R}_2$ or a group $-\text{CH}_2\text{CON}(\text{R}_7)(\text{CH}_2)_q\text{CN}$ to be prepared by reacting the acid chloride, prepared as an intermediate, with an amine HNR_1R_2 or, respectively, with a diamine $\text{HN}(\text{R}_7)(\text{CH}_2)_p\text{NR}_1\text{R}_2$ or with an amino compound $\text{HN}(\text{R}_7)(\text{CH}_2)_q\text{CN}$.

By reacting the compounds of formula I in which R represents a $-\text{CH}_2\text{CONH}_2$ group with sodium peroxide, the compounds of formula I in which R represents a carboxymethyl group are obtained. During the preparation of the compounds of formula I in which R represents a $-\text{CH}_2\text{CONH}_2$ group from the compounds of formula II in which R represents a $-\text{CH}_2\text{CONH}_2$ group, the compounds of formula I in which R represents a $-\text{CH}_2\text{CN}$ group are also obtained, which compounds are separated by chromatography. By reduction of the compounds of formula I in which R represents a $-\text{CH}_2\text{CN}$ group, for example by hydrogenation in the presence of a catalyst such as Raney® nickel, the compounds of formula I in which R represents a $-\text{CH}_2\text{CH}_2\text{NH}_2$ group are obtained. These latter compounds enable compounds of formula I in which R represents a group $-\text{CH}_2\text{CH}_2\text{NR}_1\text{R}_2$, a group $-\text{CH}_2\text{CH}_2\text{N}(\text{R}_7)\text{COR}_3$, a group $-\text{CH}_2\text{CH}_2\text{N}(\text{R}_7)\text{SO}_2\text{R}_8$ to be prepared by methods known to a person skilled in the art.

The compounds of formula II'a or, respectively, the compounds of formula II' or the compounds of formula I' in which R' represents a nitro group may be converted to the compounds of formula II'a or, respectively, of formula II' or formula I' in which R' is an amino group; then, by known methods, the compounds of formula IIa or, respectively, of formula II or formula I in which R represents a group $-\text{N}(\text{R}_7)\text{COR}_3$, a group $-\text{N}(\text{R}_7)\text{CO}(\text{CH}_2)_n\text{NR}_1\text{R}_2$, a group $-\text{N}(\text{R}_7)\text{CO}(\text{CH}_2)_n\text{NHCOR}_3$, a group $-\text{N}(\text{R}_7)\text{SO}_2\text{R}_8$, a group

$-N(R_7)CONR_9R_{10}$ or a group $-N(R_7)CO(CH_2)_qCN$ are prepared.

The compounds of formula II'a or, respectively, of formula II' or formula I' in which R' is an amino group also enable compounds of formula II'a or, respectively, of formula II' or formula I' in which R' represents a hydroxyl group to be prepared; then, by known methods, the compounds of formula IIa or, respectively, of formula II or formula I in which R represents a group $-O(CH_2)_nNR_1R_2$, a group $-O(CH_2)_nCONR_1R_2$, a group $-O(CH_2)_nCOOR_7$ or a group $-O(CH_2)_nSO_2NR_1R_2$ are prepared.

The compounds of formula I in which R is a cyano group enable the compounds of formula I in which R is a carbamoyl group to be prepared by reaction with hydrogen peroxide in the presence of a base such as sodium hydroxide. Likewise, the compounds of formula II in which R is a carbamoyl group are obtained from the compounds of formula IIa in which R is a cyano group.

The compounds of formula I in which R is a cyano group also enable the compounds of formula I in which R represents a $-C(NH_2)-NOH$ group to be prepared, by reaction with hydroxylamine in the presence of a base such as potassium carbonate.

By reduction of the compounds of formula IIa or, respectively, of formula II or formula I in which R represents a cyano group, for example by hydrogenation in the presence of a catalyst such as platinum oxide, followed by reaction with a suitable acid chloride or anhydride or, respectively, with a sulphonyl chloride, the compounds of formula IIa or, respectively, of formula II or formula I in which R represents a group $-CH_2NHCOR_3$ or, respectively, $-CH_2NHSO_2R_8$ are obtained. Similarly, the compounds of formula IIa or, respectively, of formula II or formula I in which R represents a group $-CH_2N(R_7)COR_3$ or a group $-CH_2N(R_7)SO_2R_8$, with R_7 other than hydrogen, are obtained by performing an alkylation reaction on the amine obtained as an intermediate.

The compounds of formula II'a in which R'

represents a carboxyl group enable the compounds of formula IIa in which R represents a group $-\text{CONR}_1\text{R}_2$ or, respectively, a group $-\text{CON}(\text{R}_7)(\text{CH}_2)_p\text{NR}_1\text{R}_2$ or a group $-\text{CON}(\text{R}_7)(\text{CH}_2)_q\text{CN}$ to be prepared by reacting the acid chloride, prepared as an intermediate, with an amine HNR_1R_2 or, respectively, with an amine $\text{HN}(\text{R}_7)(\text{CH}_2)_p\text{NR}_1\text{R}_2$ or with an amine $\text{HN}(\text{R}_7)(\text{CH}_2)_q\text{CN}$.

Reaction of the compounds of formula I in which R represents a group $-\text{CON}(\text{R}_7)(\text{CH}_2)_q\text{CN}$, a group $-\text{CH}_2\text{CON}(\text{R}_7)(\text{CH}_2)_q\text{CN}$, a group $-\text{N}(\text{R}_7)\text{CO}(\text{CH}_2)_q\text{CN}$ or a group $-\text{SO}_2\text{N}(\text{R}_7)(\text{CH}_2)_q\text{CN}$ with hydrochloric acid in alcoholic solution enables the corresponding imide to be obtained as an intermediate. If the imide is reacted with an equimolar amount of amine $\text{HNR}_{14}\text{R}_{15}$, the compounds of formula I in which R represents a group $-\text{CON}(\text{R}_7)(\text{CH}_2)_q\text{C}(\text{NR}_{14}\text{R}_{15})=\text{NR}_{16}$, a group $-\text{CH}_2\text{CON}(\text{R}_7)(\text{CH}_2)_q\text{C}(\text{NR}_{14}\text{R}_{15})=\text{NR}_{16}$, a group $-\text{N}(\text{R}_7)\text{CO}(\text{CH}_2)_q\text{C}(\text{NR}_{14}\text{R}_{15})=\text{NR}_{16}$ or a group $-\text{SO}_2\text{N}(\text{R}_7)(\text{CH}_2)_q\text{C}(\text{NR}_{14}\text{R}_{15})=\text{NR}_{16}$ with $\text{R}_{16} = \text{H}$, are obtained. If the imide is reacted with an excess of amine $\text{HNR}_{14}\text{R}_{15}$, the compounds of formula I in which R represents a group $-\text{CON}(\text{R}_7)(\text{CH}_2)_q\text{C}(\text{NR}_{14}\text{R}_{15})=\text{N}-\text{R}_{16}$, a group $-\text{CH}_2\text{CON}(\text{R}_7)(\text{CH}_2)_q\text{C}(\text{NR}_{14}\text{R}_{15})=\text{NR}_{16}$, a group $-\text{N}(\text{R}_7)\text{CO}(\text{CH}_2)_q\text{C}(\text{NR}_{14}\text{R}_{15})=\text{NR}_{16}$ or a group $-\text{SO}_2\text{N}(\text{R}_7)(\text{CH}_2)_q\text{C}(\text{NR}_{14}\text{R}_{15})=\text{NR}_{16}$ with R_{16} other than hydrogen, are obtained. If the imide is reacted with ethylenediamine, unsubstituted or N-substituted with a (C_1-C_4) alkyl, or with 1,3-diaminopropane, unsubstituted or N-substituted with a (C_1-C_4) alkyl, the compounds of formula I in which R represents a group $-\text{CON}(\text{R}_7)(\text{CH}_2)_q\text{C}(\text{NR}_{14}\text{R}_{15})=\text{N}-\text{R}_{16}$, a group $-\text{CH}_2\text{CON}(\text{R}_7)(\text{CH}_2)_q\text{C}(\text{NR}_{14}\text{R}_{15})=\text{NR}_{16}$, a group $-\text{N}(\text{R}_7)\text{CO}(\text{CH}_2)_q\text{C}(\text{NR}_{14}\text{R}_{15})=\text{NR}_{16}$ or a group $-\text{SO}_2\text{N}(\text{R}_7)(\text{CH}_2)_q\text{C}(\text{NR}_{14}\text{R}_{15})=\text{NR}_{16}$, in which R_{14} and R_{16} together constitute an ethylene or trimethylene group and R_{15} represents a hydrogen or a (C_1-C_4) alkyl, are obtained.

The compounds of formula I in which R represents a carbamoyl group monosubstituted on the

nitrogen enable the compounds of formula I in which R represents a group $-C(NR_4R_5)=N-R_6$ to be prepared by reaction with phosphorus pentachloride followed by reaction with an amine HNR_4R_5 .

5 The amino acids of formula III include, for example, glycine, alanine, leucine, norleucine, isoleucine, valine, 1-adamantylglycine, 2-adamantylglycine, cyclopropylglycine, cyclopentylglycine, cyclohexylglycine, cycloheptylglycine, 1-aminocyclopropanecarboxylic acid, 1-aminocyclobutanecarboxylic acid, 10 1-aminocyclopentanecarboxylic acid, 1-aminocyclohexanecarboxylic acid, 1-aminocycloheptanecarboxylic acid, 1-amino-4-methylcyclohexanecarboxylic acid, 2-amino-2-adamantanecarboxylic acid, 2-aminobicyclo[3.2.1]octane-15 2-carboxylic acid, 9-aminobicyclo[3.3.1]nonane-9-carboxylic acid and 2-aminobicyclo[2.2.1]heptane-2-carboxylic (or 2-amino-2-norbornanecarboxylic) acid.

 The amino acids of formula III are commercial products or may be very readily prepared according to 20 standard methods. In particular, the non-commercial amino acids (III) are prepared according to the Strecker synthesis, Ann, 1850, 75, 27 or according to the synthesis of H.T. Bucherer et al., J. Pract. Chem., 1934, 141, 5, followed by a hydrolysis to yield the 25 amino acids; for example, 2-amino-2-adamantanecarboxylic acid is prepared according to H.T. Nagasawa et al., J. Med. Chem., 1973, 16, (7), 823.

α -Amino-1-adamantylacetic and α -amino-2-adamantylacetic acids are prepared according to B. Gaspert et 30 al., Croatica Chemica Acta, 1976, 48 (2), 169-178.

 2-Amino-2-norbornanecarboxylic acid is prepared according to H.S. Tager et al., J. Am. Chem. Soc., 1972, 94, 968.

α -Aminocycloalkylcarboxylic acids are prepared 35 according to J.W. Tsang et al., J. Med. Chem., 1984, 27, 1663.

 (R)- and (S)-cyclopentylglycines are prepared according to European Patent Application EP 477,049.

 (R)- and (S)-cyclohexylglycines are prepared

according to Rudman et al., J. Am. Chem. Soc., 1952, 74, 551.

(R)- and (S)-cyclohexylglycines may also be prepared by catalytic hydrogenation of (R)- and (S)-phenylglycines.

α -Aminocycloalkylcarboxylic acids of R or S configuration may also be prepared by stereospecific enzymatic hydrolysis of the corresponding racemic N-acetyl derivatives according to J. Hill et al., J. Org. Chem., 1965, 1321.

The compounds of formula I and their salts possess a very great affinity for human neurotensin receptors in the tests described in the publication of D. Gully et al. cited above. More especially, relative to the 1-naphthyl and 4-chloro-1-naphthyl derivatives described in EP 0,477,049, which have an IC₅₀ equal to or greater than 100 nM, the compounds of the invention possess a markedly lower IC₅₀, ranging from 1 nM to 50 nM. Special importance attaches to the products of formula I in which T is methyl and R is aminocarbonyl; aminocarbonylmethyl; acetamido; N-methyl-N-[3-(N',N'-dimethylamino)propyl]aminosulphonyl; carbamoylmethoxy; N-[3-(N',N'-dimethylamino)propyl]aminocarbonyl; N-[2-(N',N'-dimethylamino)ethyl]aminocarbonyl. These compounds are hence even more active than SR 48692, which is unexpected if reference is made to the activity of the 1-naphthyl-3-pyrazolecarboxamides described in EP 0,477,049.

The compounds of formula I and their salts were studied in vivo. Working according to the technique described by M. Poncelet et al. in Naunyn Schmiedberg's Arch. Pharmacol., 1994, 60, 349-357, it is observed that the compounds according to the invention, administered orally, antagonize the contralateral pivoting induced by unilateral intrastriatal injection of neurotensin in mice.

Moreover, working according to the technique described by D. Nisato et al. in Life Sciences, 1994, 54, 7, 95-100, it is found that the compounds according

to the invention, administered intravenously, inhibit the increase in blood pressure induced by intravenous injection of neurotensin in anaesthetized guinea pigs.

The compounds described in Patent EP 0,477,049
5 exhibit a lower activity in these tests than that of the compounds according to the present invention.

The compounds of the present invention and their pharmaceutically acceptable salts are of low toxicity; in particular, their acute toxicity is
10 compatible with their use as a medicinal product. For such a use, an effective amount of a compound of formula I, or of one of its pharmaceutically acceptable salts, is administered to mammals for the treatment of neurotensin-dependent pathologies. Thus, the compounds
15 of the present invention may be used for the treatment of neuropsychiatric disorders, especially those associated with a dysfunction of the dopaminergic systems, for example psychoses, more especially schizophrenia and diseases of movement such as
20 Parkinson's disease (D.R. Handrich et al., Brain Research, 1982, 231, 216-221 and C.B. Nemeroff, Biological Psychiatry, 1980, 15 (2), 283-302). They may be used to diagnose and/or treat malignant neoplastic diseases, for example human meningiomas which are not
25 surgically accessible (P. Mailloux, Peptides, 1990, 11, 1245-1253), cancers of the prostate (I. Sehgal et al., Proc. Nat. Acad. Sci., 1994, 91, 4673-4677) and small cell cancers of the lung (T. Sethi et al., Cancer Res., 1991, 51, 3621-3623). They may be used in the treatment
30 of motor, secretory, ulcerous and/or tumoral gastrointestinal disorders (review by A. Shulkes in "Gut Peptides: Biochemistry and Physiology, Ed. J. Waish and G.J. Dockray, 1994"). Thus, the compounds I according to the invention may be used in the treatment of
35 complaints such as: irritable bowel syndrome, diarrhoea, colitis, ulcers, tumours of the gastrointestinal tract, dyspepsia, pancreatitis and oesophagitis. The compounds according to the invention may be indicated in the case of cardiovascular

disorders, and also in the case of pathologies associated with a histamine release such as inflammatory processes (D.E. Cochrane et al., Faseb J., 1994, 8, 7, 1195). The compounds of the present invention may also be of value in analgesia, by acting on the effects of morphine (M.O. Urban, J. Pharm. Exp. Ther., 1993, 265, 2, 580-586).

Thus, the subject of the present invention, according to another of its aspects, is pharmaceutical compositions containing as active principles the compounds of formula I or their possible pharmaceutically acceptable salts.

In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal or rectal administration, the active principles may be administered, in single-dose administration forms, as a mixture or with standard pharmaceutical vehicles, to animals and human beings. Suitable single-dose administration forms comprise forms for oral administration, such as tablets, gelatin capsules, powders, granules and oral solutions or suspensions, forms for sublingual and buccal administration, forms for subcutaneous, intramuscular or intravenous administration and forms of rectal administration.

In order to obtain the desired effect, the dose of active principle can vary between 0.5 and 1000 mg per day, and preferably between 2 and 500 mg.

Each single dose can contain from 0.5 to 250 mg of active principle, and preferably from 1 to 125 mg, in combination with a pharmaceutical vehicle. This single dose can be administered 1 to 4 times daily.

When a solid composition is prepared in the form of tablets, the active principle is mixed with a pharmaceutical vehicle such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic or the like. It is possible to coat the tablets with sucrose or with other suitable substances, or they may alternatively be treated in such a way as to have a

sustained or delayed activity and to release continuously a predetermined amount of active principle.

5 A gelatin capsule preparation is obtained by mixing the active principle with a diluent and pouring the mixture obtained into soft or hard gelatin capsules.

10 A preparation in syrup or elixir form can contain the active principle together with a sweetener, preferably a zero-calorie sweetner, and methylparaben and propylparaben as antiseptic, as well as an agent imparting flavour and a suitable colorant.

15 The water-dispersible powders or granules can contain the active principle mixed with dispersing agents or wetting agents, or suspending agents, such as polyvinylpyrrolidone and the like, as well as with sweeteners or flavour correctors.

20 For rectal administration, suppositories are employed, which are prepared with binding agents melting at rectal temperature, for example cocoa butter or polyethylene glycols.

25 For parenteral administration, aqueous suspensions, isotonic saline solutions or sterile and injectable solutions are used, which contain pharmacologically compatible dispersing and/or wetting agents, for example propylene glycol or butylene glycol.

The active principle may also be formulated in the form of microcapsules, optionally with one or more vehicles or additives.

30 To improve the solubility of the products of the invention, the compounds of formula I or their pharmaceutically acceptable salts may also be presented in the form of complexes with cyclodextrins.

35 In the description and in the examples, the following abbreviations are used:

MeOH: methanol

EtOH: ethanol

Ether: ethyl ether

Iso ether: isopropyl ether

AcOEt: ethyl acetate
MeCN: acetonitrile
DCM: dichloromethane
DMF: dimethylformamide
5 DMSO: dimethyl sulphoxide
THF: tetrahydrofuran
HCl: hydrochloric acid
AcOH: acetic acid
TFA: trifluoroacetic acid
10 H₂SO₄: sulphuric acid
NaOH: sodium hydroxide
KOH: potassium hydroxide
NH₄OH: aqueous ammonia
Na₂SO₄: sodium sulphate
15 P₂O₅: phosphorus pentoxide
Me, MeO: methyl, methoxy
Et: ethyl
M.p.: melting point
RT: room temperature
20 Silica H: silica gel 60 H marketed by MERCK
(DARMSTAD)
NMR: nuclear magnetic resonance
s: singlet
bs: broad singlet
25 d: doublet
t: triplet
qr: quartet
qt: quintet
u.c.: unresolved complex
30 mt: multiplet

Preparation 1

Methyl 4-(2,6-dimethoxyphenyl)-4-oxido-2-oxo-3-butenate sodium salt.

35 A solution of 100 g of 2,6-dimethoxyacetophenone and 7.5 ml of ethyl oxalate in 520 ml of anhydrous MeOH is added slowly to a solution of sodium methylate prepared from 12.7 g of sodium and 285 ml of anhydrous MeOH. The reaction mixture is heated to reflux for 7 hours and left overnight at RT. It is

poured into 2 litres of iso ether and left stirring for 15 minutes. The expected product is obtained by filtration, washing with iso ether and drying under vacuum, m = 120 g, m.p. = 178°C.

5 PREPARATIONS OF THE HYDRAZINES 3

Preparation 2.1

1-Hydrazino-4-nitronaphthalene hydrochloride.

A solution of 1.9 g of sodium nitrite in 10 ml of water is added to a suspension, cooled to -5°C, of
10 5.2 g of 4-nitro-1-naphthylamine in 150 ml of concentrated HCl, 100 ml of 1N HCl and 150 ml of AcOH. The mixture is left stirring for 1 hour 15 minutes at a temperature of between -5°C and 0°C. It is cooled to -15°C, and a solution of 12.5 g of stannous chloride
15 dihydrate in 30 ml of concentrated HCl is added very slowly. The temperature is allowed to rise to RT and the reaction mixture is kept stirring for 2 hours 30 minutes. It is filtered, the solid is then taken up with water and the mixture is filtered again. 5.9 g of
20 the expected product are obtained.

Preparation 2.2

4-Cyano-1-hydrazinonaphthalene.

A solution of 4.09 g of sodium nitrite in 30 ml of water is added to a solution, cooled to 0°C, of
25 8.35 g of 4-cyano-1-naphthylamine in 180 ml of 1N HCl. The mixture is left stirring for 1 hour 15 minutes at 0°C. It is cooled to -10°C, and a solution of 41.75 g of stannous chloride dihydrate in 42 ml of concentrated HCl is added slowly. The reaction mixture is stirred
30 for 1 hour, allowing the temperature to rise to RT. It is filtered. The residue is suspended in water and 20 ml of concentrated NaOH are added. The expected product is obtained after filtration, rinses with water and then drying under vacuum, m = 8.6 g.

35 Preparation 2.3

4-Hydrazino-1-naphthalenesulphonic acid hydrochloride.

4 g of NaOH are added to a suspension of 22.33 g of 4-amino-1-naphthalenesulphonic acid in

125 ml of water. The mixture is cooled to 0°C and 2 ml of concentrated NaOH are added, followed by 7.5 g of sodium nitrite and 125 g of ice to maintain the temperature at 0°C. The suspension thereby obtained is poured into 75 ml of concentrated HCl cooled beforehand to 0°C, and left stirring for 2 hours 15 minutes at this temperature. The reaction mixture is added slowly to a solution, cooled beforehand to -10°C, of 55 g of stannous chloride dihydrate in 50 ml of concentrated HCl and 25 ml of water. After one night, the expected product is obtained by filtration, rinsing with 1N HCl and with water, m = 23.96 g.

Preparation 2.4

4-Hydrazino-1-naphthaleneacetic acid hydrochloride.

A) 4-Amino-1-naphthaleneacetic acid hydrochloride.

This compound is prepared according to the method described by Y. Ogata et al., J. Org. Chem., 1951, 16, 1588.

B) 4-Hydrazino-1-naphthaleneacetic acid hydrochloride.

3.18 g of the compound obtained in the preceding step are mixed at -5°C with 30 ml of concentrated HCl and 30 ml of AcOH. A solution of 1 g of sodium nitrite in 15 ml of water is added rapidly and the mixture is left stirring for 2 hours at a temperature of between -5°C and +4°C. A solution of 14.2 g of stannous chloride dihydrate in 19 ml of concentrated HCl is then added, and the mixture is left stirring for 30 minutes at 0°C. The temperature is allowed to rise to RT and the reaction mixture is left stirring for 1 hour. It is filtered, and the crystals collected are stirred for 1 hour in MeCN. The expected product is obtained after filtration, m = 2.4 g, m.p. = 180°C.

Preparation 2.5

4-Hydrazino-1-naphthalenecarboxylic acid hydrochloride.

A) 4-Amino-1-naphthalenecarboxylic acid methanesulphonate.

2.8 ml of a 1.6 M solution of n-butyllithium in hexane are added under an argon atmosphere to a solution, cooled to -15°C , of 5 g of 4-bromo-1-naphthylamine in 90 ml of ether, and the mixture is left stirring for 1 hour at -15°C . A solution of 5 g of 1,2-bis(chlorodimethylsilyl)ethane in 50 ml of ether is then added, the mixture is left stirring for 30 minutes at -10°C and the temperature is allowed to rise to RT. The mixture is cooled to -5°C , 15 ml of a 1.6 M solution of n-butyllithium in hexane are added and the mixture is left stirring for 1 hour at 0°C . A stream of carbon dioxide is then bubbled into the reaction mixture for 2 hours at a temperature of between 0 and 5°C . 2.86 ml of chlorotrimethylsilane are then added and the mixture is left stirring for 30 minutes. Water is then added, the mixture is extracted with AcOEt, the organic phase is dried over Na_2SO_4 and the solvent is evaporated off under vacuum. The residue is dissolved in acetone, 1.46 ml of methanesulphonic acid are added, and the precipitate formed is drained and washed with ether. 4 g of the expected product are obtained, m.p. = 180°C (dec.).

This compound is also obtained according to the procedure described below.

A') 4-Amino-1-naphthalenecarboxylic acid.

A mixture of 32 g of 4-cyano-1-naphthylamine in 400 ml of a 50 % solution of KOH in water is heated to reflux overnight. After cooling, 800 ml of water are added to the reaction mixture and some insoluble matter is filtered off. The filtrate is cooled to $+5^{\circ}\text{C}$ and acidified to pH 5 by adding concentrated HCl. The precipitate formed is drained and, after drying, 35 g of the expected product are obtained.

This compound is also obtained according to the two steps of the process described below.

A'') 4-Nitro-1-naphthalenecarboxylic acid.

This compound is prepared according to J. Am.

Chem. Soc., 1929, 51, 1831-1836, from 4-nitro-1,8-naphthalic anhydride.

B") 4-Amino-1-naphthalenecarboxylic acid hydrochloride.

5 A mixture of 35 g of the compound prepared in step A", 1 litre of MeOH and 200 ml of DMF is hydrogenated in a Parr apparatus under a pressure of 8 bars and in the presence of Raney® nickel. After 4 hours the catalyst is filtered off and the filtrate
10 is evaporated under vacuum. The residue is taken up in water, the mixture is left stirring overnight and the precipitate is drained. The precipitate is dissolved in a saturated solution of hydrochloric acid in MeOH, and ether is added until precipitation occurs. After
15 draining and then drying, 21.4 g of the expected product are obtained.

B) 4-Hydrazino-1-naphthalenecarboxylic acid hydrochloride.

20 2.4 g of 4-amino-1-naphthalenecarboxylic acid hydrochloride are mixed at 0°C with 80 ml of concentrated HCl. A solution of 0.89 g of sodium nitrite in 19 ml of water is added and the mixture is left stirring for 2 hours at 2-3°C. It is cooled to -10°C, and a solution of 9.7 g of stannous chloride dihydrate
25 in 90 ml of concentrated HCl is added slowly. The temperature is allowed to rise to RT and the mixture is kept stirring for 30 minutes. 200 ml of water are added, the mixture is left stirring for 30 minutes and the solid formed is drained. The solid is taken up in
30 MeCN, drained, washed with ether and dried. 2.2 g of the expected product are obtained, m.p. = 190°C.

This compound is also obtained according to the three steps of the process described below.

A'') N-ter-butoxycarbonyl-4-bromo-1-naphtylamine.
35

A mixture of 5g of 4-bromo-1-naphtylamine and 6.4g of di-tert-butyldicarbonate in 120ml of tert-butanol is heated to reflux for 20 hours. The reaction mixture thereby obtained is poured into 250ml of

water ; the precipitate so formed is drained, washed with water, dissolved into DCM and the organic phase is dried over Na_2SO_4 and the solvent is evaporated off under vacuum. 6.9g of the expected product are obtained ; m.p. = 134°C .

5 B'') 4-tert-butoxycarbonylaminonaphtalene-1-carboxylic acid.

21.3ml of a solution of 1.6 M n-butyllithium in hexane is added under nitrogen atmosphere to a solution of 5g of the compound obtained in step A'') in 100 ml of ether, cooled to -10°C . The mixture is left stirring for 1 hour 30 minutes at 0°C . The reaction mixture is cooled to -10°C and a stream of carbon dioxide is then bubbled into the reaction mixture for 15 minutes. Then 15 250ml of water are added and after decantation the aqueous phase is washed with ether. The aqueous phase is then acidified to pH6 by adding AcOH, extracted with DCM, the organic phase is dried over Na_2SO_4 and the solvent is evaporated off under vacuum. 2.7g of the 20 expected product are obtained, m.p. = 214°C .

C'') Methanesulfonate of the 4-aminonaphtalene-1-carboxylic acid.

A solution of 15.8ml of methanesulfonic acid in 50ml of DCM is added dropwise at RT into a suspension of 7g of the compound obtained in step B'') in 70ml of 25 DCM. After stirring at RT for 45 minutes, 150ml of ether are added to the reaction mixture and the precipitate so formed is drained. After washing of the precipitate with ether and drying, 6.5g of the expected 30 product are obtained ; m.p. = 196°C (decomposition).

Preparation 2.6

4-Hydrazino-1,8-naphthalimide hydrochloride.

A) 4-Sulpho-1,8-naphthalimide potassium salt.

A mixture of 25 g of 4-sulpho-1,8-naphthalic anhydride potassium salt and 300 ml of 30 % aqueous ammonia solution is left stirring for 2 hours at $60-70^\circ\text{C}$. After one night at RT, the precipitate formed is drained and washed with water and then with EtOH. 21 g of the expected product are obtained, m.p. $> 300^\circ\text{C}$.

B) 4-Hydrazino-1,8-naphthalimide hydrochloride.

A mixture of 7 g of the compound obtained in the preceding step, 3.5 ml of hydrazine monohydrate and 100 ml of water is heated for 4 days to 80°C. After cooling, it is acidified to pH 1 by adding 1N HCl, and the precipitate formed is drained. 3.5 g of the expected product are obtained after trituration in an EtOH/ether mixture, followed by draining, m.p. = 278°C.

Preparation 2.7

N-Amino-4-hydrazino-1,8-naphthalimide (compound 5)

A mixture of 25 g of 4-sulpho-1,8-naphthalic anhydride potassium salt and 50 ml of hydrazine monohydrate is heated to 120°C for 1.5 days. After cooling, water is added to the reaction mixture, and the precipitate formed is drained and dried. 15.7 g of the expected product are obtained, m.p. = 260°C.

PREPARATIONS OF THE ESTERS IIa, II'a and II"a

Preparation 3.1

5-(2,6-Dimethoxyphenyl)-1-(4-nitro-1-naphthyl)-3-pyrazolecarboxylic acid methyl ester.

(II'a: R' = NO₂; T = Me).

A mixture of 10 g of the compound obtained in Preparation 2.1, 13.5 g of compound obtained in Preparation 1 and 200 ml of AcOH is heated to reflux for 5 hours 30 minutes. After filtering off the insoluble matter, the filtrate is poured into 2 litres of a mixture of water and ice. The precipitate obtained is filtered off and stirred in 300 ml of iso ether. 14.8 g of the expected product are obtained after filtration, m.p. = 180°C.

Preparation 3.2

1-(4-Cyano-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolecarboxylic acid methyl ester.

(IIa: R = CN, T = Me).

A mixture of 8.6 g of the compound obtained in Preparation 2.2, 13.5 g of compound obtained in

Preparation 1 and 85 ml of AcOH is heated to reflux for 5 hours 15 minutes. After one night at RT, the reaction mixture is poured into a mixture of water and ice. The precipitate obtained is filtered off and washed with water. The product is chromatographed on silica, eluting with DCM and then DCM/AcOEt (98:2; v/v). 5.38 g of the expected product are obtained, m.p. = 165°C.

Preparation 3.3

5-(2,6-Dimethoxyphenyl)-1-(4-sulpho-1-naphthyl)-3-pyrazolecarboxylic acid methyl ester.

(II'a: R' = SO₃H, T = Me).

A mixture of 22.9 g of the compound obtained in Preparation 2.3, 21.65 g of compound obtained in Preparation 1 and 150 ml of AcOH is heated to reflux for 2 hours. After cooling, the reaction mixture is poured into a mixture of water and ice, and the precipitate obtained is filtered off. The filtrate is cooled and the pH is adjusted to 5-6 by adding concentrated NaOH. The precipitate obtained is filtered off and washed with water. 28.66 g of the expected product are obtained, m.p. = 236°C.

Preparation 3.4

1-[4-(Carboxymethyl)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolecarboxylic acid methyl ester.

(IIa: R = -CH₂COOH; T = Me).

A mixture of 2.4 g of the compound obtained in Preparation 2.4, 2.8 g of the compound obtained in Preparation 1 and 50 ml of AcOH is heated for 2 hours 30 minutes to 60-70°C. After cooling, water is added to the mixture and the viscous oil formed is separated. This oil is dissolved in EtOH and added slowly to the aqueous solution. The mixture is stirred for 1 hour and the precipitate obtained is filtered off. 2.8 g of the expected product are obtained, m.p. = 200°C.

Preparation 3.5

5-(2,6-Dimethoxyphenyl)-1-[4-(ethanecarboxamido)-1-naphthyl]-3-pyrazolecarboxylic acid methyl ester.

(IIa: R = NHCOEt; T = Me).

A mixture of 0.87 g of the compound obtained in Preparation 3.1, 0.3 g of 10 % palladium on charcoal and 5 ml of propionic anhydride in 5 ml of DMF is hydrogenated at 80°C at atmospheric pressure for 33 hours. 0.5 ml of pyridine is then added and the mixture is left stirring overnight at RT. It is filtered through Celite®, the filter is rinsed with MeOH and the filtrate is evaporated under vacuum. It is chromatographed on silica H, eluting with a toluene/AcOEt (70:30; v/v) mixture. 0.45 g of the expected product is obtained, m.p. = 110°C.

Preparation 3.6

1-[4-(Acetylaminomethyl)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolecarboxylic acid methyl ester.

(IIa: R = -CH₂NHCOMe; T = Me).

A mixture of 2 g of the compound obtained in Preparation 3.2, 30 ml of acetic anhydride and 0.2 g of platinum oxide is hydrogenated at atmospheric pressure for 12 hours at 60°C and then 8 hours at 100°C. After filtration through Celite® and washing with AcOEt, water is added to the filtrate. The latter is extracted with AcOEt, the organic phase is dried over sodium sulphate and the solvent is evaporated off under vacuum. The expected product is obtained after chromatography on silica H, eluting with a gradient of a DCM/AcOEt (98:2; v/v to 60:40; v/v) mixture. 0.9 g of the expected product is obtained.

NMR spectrum at 200 MHz in DMSO:

1.95 ppm : s : 3H
3.5 ppm : bs: 6H
3.9 ppm : s : 3H
4.75 ppm : d : 2H
6.55 ppm : d : 2H
6.95 ppm : s : 1H
7.15 to 8.25 ppm : u.c. : 7H
8.5 ppm : t : 1H

Preparation 3.7

5-(2,6-Dimethoxyphenyl)-1-[4-(dimethylamino-sulphonyl)-1-naphthyl]-3-pyrazolecarboxylic acid methyl

ester.

(IIa: R = -SO₂N(Me)₂; T = Me).

A) 1-[4-(Chlorosulphonyl)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolecarboxylic acid methyl ester.

(II'a: R' = -SO₂Cl; T = Me).

A mixture of 5 g of the compound obtained in Preparation 3.3 and 3.21 g of phosphorus pentachloride in 100 ml of DCM is stirred at RT for 5 hours. The mixture is evaporated to dryness under vacuum and the residue is heated to 110°C for 1 hour. It is left overnight at RT. The residue is taken up several times with toluene, DCM and 1,2-dichloroethane, followed each time by an evaporation under vacuum. 5.9 g of the expected product are obtained, which product is used in the next step without further treatment.

B) 5-(2,6-Dimethoxyphenyl)-1-[4-(dimethylamino-sulphonyl)-1-naphthyl]-3-pyrazolecarboxylic acid methyl ester.

(IIa: R = -SO₂N(Me)₂, T = Me).

Gaseous dimethylamine is introduced for 45 minutes into a solution of 5.9 g of the compound obtained in the preceding step in 100 ml of DCM to which 1,2-dichloroethane and DMF are added until the compound has dissolved. The mixture is then left stirring at RT for 3 hours 30 minutes. After filtering off some insoluble matter, the filtrate is evaporated under vacuum. The residue is extracted with AcOEt, the organic phase is washed with water and dried over sodium sulphate and the solvent is evaporated off under vacuum. 2.67 g of the expected product are obtained.

NMR spectrum at 200 MHz in DMSO:

2.65 ppm : s : 6H

3.35 ppm : bs : 6H

6.45 ppm : d : 2H

6.95 ppm : s : 1H

7.15 ppm : t : 1H

7.3 to 8.8 ppm : u.c. : 6H

Preparation 3.8

5-(2,6-Dimethoxyphenyl)-1-[4-(N-methyl-N-[3-(N',N'-dimethylamino)propyl]aminosulphonyl)-1-naphthyl]-3-pyrazolecarboxylic acid methyl ester.

(IIa: R = -SO₂N(Me)(CH₂)₃N(Me)₂; T = Me).

5 2.34 g of the compound obtained in step A of Preparation 3.7 are dissolved under reflux in 50 ml of toluene, the mixture is cooled to RT and 1.4 ml of N,N,N'-trimethyl-1,3-propanediamine are added. The mixture is then stirred at RT for 2 hours 45 minutes and 0.7 ml of N,N,N'-trimethyl-1,3-propanediamine is added. After 45 minutes of stirring at RT, some insoluble matter is filtered off and the filtrate is evaporated under vacuum. The residue is extracted with AcOEt, the organic phase is washed with water and dried over sodium sulphate and the solvent is evaporated off under vacuum. The product is chromatographed on silica, eluting with a DCM/MeOH (100:6; v/v) mixture. 0.82 g of the expected product is obtained, m.p. = 87°C.

Preparation 3.9

20 1-[4-(Carbamoylmethyl)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolecarboxylic acid methyl ester.

(IIa: R = -CH₂CONH₂; T = Me).

25 A mixture of 1.4 g of the compound obtained in Preparation 3.4 and 3 ml of thionyl chloride in 30 ml of DCM is heated to 40°C for 3 hours; it is then evaporated to dryness under vacuum. A solution of the acid chloride prepared above in THF is added to 20 ml of a 0.4N solution of ammonia in THF. The reaction mixture is left stirring overnight at RT and evaporated under vacuum. The residue is taken up in water and the precipitate formed is filtered off. The expected product is obtained, which product is used in Preparation 4.8 without further treatment.

35 Preparation 3.10

1-(4-Amino-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolecarboxylic acid methyl ester.

(II'a: R' = NH₂; T = Me).

A mixture of 7.5 g of the compound prepared in

Preparation 3.1 and 0.75 g of Raney® nickel in 200 ml of MeOH is hydrogenated at RT for 6 days at atmospheric pressure. The reaction mixture is filtered through Celite®, the filter is washed with 100 ml of DMF and
5 the solvents are evaporated off under vacuum. 0.7 g of the expected product is obtained after crystallization in iso ether, m.p. = 246°C.

Preparation 3.11

5-(2,6-Dimethoxyphenyl)-1-(4-hydroxy-1-naphthyl)-3-pyrazolecarboxylic acid methyl ester.
10

(II'a: R' = OH; T = Me).

A solution of 0.475 g of sodium nitrite in 25 ml of water is added to a mixture, cooled to 0°C, of 2.5 g of the compound prepared in Preparation 3.10 in
15 50 ml of 35 % H₂SO₄. The mixture is left stirring for 1 hour 30 minutes at 3°C, and 1.3 g of diazonium salt are obtained after filtering off the crystals formed, followed by drying. The diazonium salt thus prepared is added to a solution of 130 g of copper nitrate in
20 800 ml of water, and the mixture is left stirring for 30 minutes. 1 g of iron sulphate is then added and the mixture is left stirring for 2 hours. After filtration of the reaction mixture, the residue is taken up in MeOH and left stirring in the presence of animal
25 charcoal. The mixture is filtered through Celite® and the filtrate is evaporated under vacuum. 0.69 g of the expected product is obtained after crystallization in EtOH, m.p. = 240°C.

Preparation 3.12

30 5-(2,6-Dimethoxyphenyl)-1-(4-[3-(N,N-dimethyl-amino)propoxy]-1-naphthyl)-3-pyrazolecarboxylic acid methyl ester.

(IIa: R = -O(CH₂)₃N(Me)₂; T = Me).

0.44 g of the compound prepared in Preparation
35 3.11, 0.19 ml of a 50 % solution of caesium hydroxide in water and 1 ml of MeOH are mixed, and the mixture is then evaporated to dryness. The residue is taken up in 5 ml of DMF, and 0.48 g of 3-chloro-N,N-dimethylpropylamine hydrochloride is added, followed by 1.44 g of

potassium carbonate. The mixture is heated for 3 hours to 60°. After cooling, water is added, the mixture is extracted with AcOEt, the organic phase is dried over sodium sulphate and the solvent is evaporated off under vacuum. The product is chromatographed on silica, eluting with a DCM/MeOH/NH₄OH (100:5:0.5; v/v/v) mixture. 0.25 g of the expected product is obtained.

NMR spectrum at 200 MHz in DMSO:

1.9 ppm : qt : 2H
2.1 ppm : s : 6H
2.4 ppm : mt : 2H
3.35 ppm : s : 6H
3.7 ppm : s : 3H
4.1 ppm : t : 2H
6.35 ppm : d : 2H
6.8 ppm : s : 1H
6.95 to 8.1 ppm : u.c. : 7H

Preparation 3.13

1-[4-(Carbamoylmethoxy)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolecarboxylic acid methyl ester.

(IIa: R = -OCH₂CONH₂, T = Me).

0.39 g of the compound prepared in Preparation 3.11, 0.17 ml of a 50 % solution of caesium hydroxide in water and 1 ml of MeOH are mixed, and the mixture is then evaporated to dryness. The residue is taken up in 5 ml of DMF, and 0.193 g of 2-bromoacetamide is added. The mixture is heated for 2 hours to 60°. After cooling, water is added, the mixture is extracted with AcOEt, the organic phase is dried over sodium sulphate and the solvent is evaporated off under vacuum. 0.28 g of the expected product is obtained, which product is used in Preparation 4.10 without further treatment.

Preparation 3.14

1-(4-Carboxy-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolecarboxylic acid methyl ester.

(II'a: R' = -COOH; T = Me).

A mixture of 2.2 g of the compound obtained in Preparation 2.5, 2.65 g of the compound obtained in

Preparation 1 and 200 ml of AcOH is heated to reflux for 3 hours. After cooling, 700 ml of water are added and the precipitate formed is drained. The precipitate is taken up in 1,4-dioxane and the solvent is evaporated off under vacuum. After drying, 2.75 g of the expected product are obtained, m.p. = 240°C.

Preparation 3.15

5-(2,6-Dimethoxyphenyl)-1-[4-(N-[3-(N',N'-dimethylamino)propyl]carbamoyl)-1-naphthyl]-3-pyrazole-carboxylic acid methyl ester.

(IIa: R = -CONH(CH₂)₃N(Me)₂; T = Me).

A mixture of 0.5 g of the compound obtained in Preparation 3.14 and 5 ml of thionyl chloride are left stirring for 2 hours, and the mixture is then concentrated under vacuum. The acid chloride thereby obtained is taken up in 5 ml of DCM, this solution is then added dropwise to a solution of 0.165 ml of N,N-dimethyl-1,3-propanediamine and 0.172 ml of triethylamine in 10 ml of DCM, and the mixture is left stirring overnight at RT. Water is added to the reaction mixture, the organic phase is separated after settling has taken place and dried over Na₂SO₄ and the solvent is evaporated off under vacuum. 0.52 g of the expected product is obtained.

NMR spectrum at 200 MHz in DMSO:

1.8 to 2.0 ppm : mt : 2H

2.8 ppm : s : 6H

3.05 to 3.40 ppm : 2t : 4H

3.4 ppm : s : 6H

6.5 ppm : d : 2H

7.0 ppm : s : 1H

7.1 to 7.2 ppm : t : 1H

7.4 ppm : d : 1H

7.45 to 7.70 ppm : u.c. : 4H

8.20 ppm : mt : 1H

Preparation 3.16

5-(2,6-Dimethoxyphenyl)-1-[4-(N-[2-(N',N'-dimethylamino)ethyl]carbamoyl)-1-naphthyl]-3-pyrazole-carboxylic acid methyl ester.

(IIa: R = -CONH(CH₂)₂N(Me)₂; T = Me).

This compound is prepared according to the procedure described in Preparation 3.15, from 0.5 g of the compound obtained in Preparation 3.14, 5 ml of thionyl chloride and then 0.155 ml of N,N-dimethylethylenediamine and 0.196 ml of triethylamine. 0.6 g of the expected product is obtained.

NMR spectrum at 200 MHz in DMSO:

2.8 ppm : s : 6H
3.2 to 3.8 ppm : u.c. : 10H
3.9 ppm : s : 3H
6.8 ppm : d : 2H
7.0 ppm : s : 1H
7.2 ppm : t : 1H
7.4 ppm : d : 1H
7.45 to 7.70 ppm : u.c. : 3H
7.8 ppm : d : 1H
8.3 ppm : u.c. : 1H
10.2 ppm : bs : 1H

Preparation 3.17

1-{4-[N-(Cyanomethyl)carbamoyl]-1-naphthyl}-5-(2,6-dimethoxyphenyl)-3-pyrazolecarboxylic acid methyl ester.

(IIa: R = -CONHCH₂CN; T = Me).

This compound is prepared according to the procedure described in Preparation 3.15, from 1.22 g of the compound obtained in Preparation 3.14, 12 ml of thionyl chloride and then 0.269 g of aminoacetonitrile hydrochloride and 0.8 ml of triethylamine. 0.77 g of the expected product is obtained after crystallization in EtOH, m.p. = 138-140°C.

Preparation 3.18

1-{4-[N-(2-Cyanoethyl)-N-methylcarbamoyl]-1-naphthyl}-5-(2,6-dimethoxyphenyl)-3-pyrazolecarboxylic acid methyl ester.

(IIa: R = -CON(Me)CH₂CH₂CN; T = Me).

This compound is prepared according to the procedure described in Preparation 3.15, from 10 g of the compound obtained in Preparation 3.14, 15 ml of

thionyl chloride and then 2.4 ml of 3-methylamino-propionitrile and 3.3 ml of triethylamine. 12 g of the expected product are obtained.

NMR spectrum at 200 MHz in DMSO:

5 2.6 ppm : s : 3H
 2.8 ppm : t : 2H
 3.3 ppm : s : 6H
 3.9 ppm : u.c. : 5H
 6.4 ppm : d : 2H
10 6.9 ppm : s : 1H
 7.1 ppm : t : 1H
 7.2 to 7.8 ppm : u.c. : 6H

Preparation 3.19

15 5-(2,6-Dimethoxyphenyl)-1-[4-(N-methylcarbamoyl)-1-naphthyl]-3-pyrazolecarboxylic acid methyl ester.

(IIa: R = -CONHMe; T = Me).

20 A mixture of 4 g of the compound obtained in Preparation 3.14 and 20 ml of thionyl chloride in 20 ml of DCM is heated to 40°C for 2 hours and is then concentrated under vacuum. The acid chloride thereby
25 obtained is taken up in 40 ml of DCM, and the mixture is added dropwise to a solution, cooled beforehand to 5°C, of 4 ml of a 40 % aqueous solution of methylamine in 80 ml of MeOH. The mixture is left stirring overnight at RT and concentrated under vacuum, the residue
30 is taken up with water and the precipitate formed is drained. After drying, the expected product is obtained, which product is used in Preparation 4.15 without further treatment.

30 Preparation 3.20

 5-(2,6-Dimethoxyphenyl)-1-[4-(6-acetamidohexanoylamino)-1-naphthyl]-3-pyrazolecarboxylic acid methyl ester.

(IIa: R = -NHCO(CH₂)₅NHCOMe; T = Me).

35 A) 6-Acetamidohexanoyl chloride

 A mixture of 0.37 g of 6-acetamidohexanoic acid and 2.5 ml of thionyl chloride is left stirring for 24 hours at RT. It is concentrated under vacuum, and the acid chloride thereby obtained is used in the next

step without further treatment.

B) 5-(2,6-Dimethoxyphenyl)-1-[4-(6-acetamido-hexanoylamino)-1-naphthyl]-3-pyrazolecarboxylic acid methyl ester.

5 A mixture of 0.5 g of the compound obtained in Preparation 3.10 and 0.5 ml of bis(trimethylsilyl)-acetamide in 5 ml of MeCN is left stirring overnight at RT. A solution of the compound obtained in the preceding step in 5 ml of MeCN is then added, followed
10 by 2 ml of triethylamine. The mixture is left stirring for two days at RT, 5 ml of MeOH and 5 ml of water are added, and the mixture is left stirring for 15 minutes and concentrated under vacuum. The residue is extracted with 50 ml of DCM, the organic phase is washed with
15 water and with 1N HCl solution and dried over Na₂SO₄ and the solvent is concentrated under vacuum. 0.7 g of the expected product is obtained, which product is used in Preparation 4.16 without further treatment.

Preparation 3.21

20 5-(2,6-Dimethoxyphenyl)-1-[4-(N-methyl-N-[3-(N',N'-dimethylamino)propyl]carbamoyl)-1-naphthyl]-3-pyrazolecarboxylic acid methyl ester.

(IIa: R = -CON(Me)(CH₂)₃N(Me)₂; T = Me).

25 This compound is prepared according to the procedure described in Preparation 3.15, from 0.5 g of the compound obtained in Preparation 3.14, 5 ml of thionyl chloride and then 0.120 ml of N,N,N'-trimethyl-1,3-propanediamine and 0.170 ml of triethylamine. 0.43 g of the expected product is obtained.

30 Preparation 3.22

5-(2,6-Dimethoxyphenyl)-1-[4-(N-methyl-N-[2-(N',N'-dimethylamino)ethyl]carbamoyl)-1-naphthyl]-3-pyrazolecarboxylic acid methyl ester.


(IIa: R = -CON(Me)(CH₂)₂N(Me)₂; T = Me).

35 This compound is prepared according to the procedure described in Preparation 3.15 from 0.5 g of the compound obtained in Preparation 3.14, 5 ml of thionyl chloride and then 0.179 ml of N,N,N'-trimethyl-ethylenediamine and 0.2 ml of triethylamine. 0.4 g of

the expected product is obtained.

Preparation 3.23

5-(2,6-Dimethoxyphenyl)-1-[1,3(2H)-dioxo-1H-benz[de]isoquinol-6-yl]-3-pyrazolecarboxylic acid methyl ester.



A mixture of 2 g of the compound obtained in Preparation 2.6, 2.4 g of the compound obtained in Preparation 1 and 50 ml of AcOH is heated to reflux for 3 hours. After cooling, water is added and the precipitate formed is drained. The precipitate is chromatographed on silica, eluting with a DCM/MeOH (100:2; v/v) mixture. 2.4 g of the expected product are obtained, m.p. = 138°C (dec.).

Preparation 3.24

5-(2,6-Dimethoxyphenyl)-1-[2-amino-1,3(2H)-dioxo-1H-benz[de]isoquinol-6-yl]-3-pyrazolecarboxylic acid methyl ester.

(II'a: T = Me).

A mixture of 3 g of the compound obtained in Preparation 2.7, 3.6 g of the compound obtained in Preparation 1 and 70 ml of AcOH is heated to 70°C for 2 hours. It is concentrated under vacuum, the residue is taken up with water and the precipitate formed is drained and dried. The precipitate is chromatographed on silica, eluting with a DCM/AcOH (100:5; v/v) mixture. 3.3 g of the expected product are obtained, which product is used in Preparation 4.20 without further treatment.

PREPARATIONS OF THE ACIDS II, II' and II''

Preparation 4.1

5-(2,6-Dimethoxyphenyl)-1-(4-nitro-1-naphthyl)-3-pyrazolecarboxylic acid.

(II': R' = -NO₂; T = Me).

A mixture of 14.8 g of the ester obtained in Preparation 3.1, 5.8 g of KOH, 12 ml of water and 50 ml of MeOH is heated for 1 hour 30 minutes to 40°C. The solvents are evaporated off under vacuum and the residue is taken up with 250 ml of water. The mixture is acidified at 10°C to pH 1 by adding 1N HCl. The precipitate formed is filtered off and washed twice with water. 14.64 g of the expected product are obtained after recrystallization in iso ether, m.p. = 255°C.

Preparation 4.2

5-(2,6-Dimethoxyphenyl)-1-[4-(ethanecarbox-amido)-1-naphthyl]-3-pyrazolecarboxylic acid.

(II: R = -NHCOEt; T = Me).

A mixture of 0.35 g of the compound obtained in Preparation 3.5, and 0.07 g of lithium hydroxide monohydrate in 2 ml of EtOH is stirred at RT for 4 hours 30 minutes. It is evaporated under vacuum, the residue is taken up in 5 ml of 1N HCl and the mixture is left stirring for 1 hour. 0.27 g of the expected product is obtained after filtration and washes with water, m.p. = 168°C.

Preparation 4.3

1-(4-Cyano-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolecarboxylic acid.

(II: R = -CN; T = Me).

A mixture of 4.88 g of the ester obtained in Preparation 3.2 and 1.2 ml of concentrated NaOH in 500 ml of MeOH is stirred overnight at RT. The reaction mixture is heated for 3 hours to 40°C and concentrated under vacuum to one half the volume. 1.2 ml of concentrated NaOH are added and the mixture is heated for 6 hours to 40°C. After 48 hours at RT, the reaction mixture is partially concentrated and poured into a mixture of water and ice. The resulting mixture is extracted with ether, the aqueous phase is acidified to pH 4 by adding 1.2N HCl and extracted with AcOEt, the organic phase is dried over sodium sulphate and the

solvent is evaporated off under vacuum. 4.6 g of expected product are obtained, m.p. = 216°C.

Preparation 4.4

1-(4-Carbamoyl-1-naphthyl)-5-(2,6-dimethoxy-phenyl)-3-pyrazolecarboxylic acid.

(II: R = -CONH₂; T = Me).

A mixture of 1.48 g of the compound obtained in Preparation 3.2, 3 ml of 6N NaOH and 3 ml of hydrogen peroxide (33 % aqueous solution) in 15 ml of 95 % EtOH is heated to reflux for 1 hour 20 minutes. It is then stirred at RT overnight. The precipitate obtained is filtered off and rinsed with 95 % EtOH. To a suspension in water of the solid collected, concentrated HCl is added to pH 1. 0.92 g of the expected product is obtained after filtration, washes with water and drying, m.p. = 305°C.

Preparation 4.5

1-[4-(Acetylaminomethyl)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolecarboxylic acid.

(II: R = -CH₂NHCOMe; T = Me).

A mixture of 0.8 g of the compound obtained in Preparation 3.6 and 0.1 g of lithium hydroxide monohydrate in 12 ml of MeOH and 1.5 ml of water is stirred at RT for 4 days. The reaction mixture is poured into a mixture of water and ice and the resulting mixture is washed with ether. The aqueous phase is acidified to pH 2 by adding 1.2N HCl. 0.58 g of the expected product is obtained after filtering off the precipitate formed, washing with water and drying under vacuum over P₂O₅, m.p. = 252°C.

Preparation 4.6

5-(2,6-Dimethoxyphenyl)-1-[4-(dimethylamino-sulphonyl)-1-naphthyl]-3-pyrazolecarboxylic acid.

(II: R = -SO₂N(Me)₂; T = Me).

A solution of 0.6 g of KOH in 0.5 ml of water is added at RT to a solution of 2.15 g of the compound obtained in Preparation 3.7 in 15 ml of dioxane. The reaction mixture is left stirring at RT for 1 hour and then left overnight. The said mixture is partially concentrated under vacuum and left stirring at RT for 4 hours. It is poured into a mixture of water and ice and

the resulting mixture is washed with ether. The aqueous phase is acidified to pH 4-5 by adding 1.2N HCl. 2 g of the expected product are obtained after filtering off the precipitate formed, washing with water and drying under vacuum over P₂O₅, m.p. = 209°C.

Preparation 4.7

5-(2,6-Dimethoxyphenyl)-1-[4-(N-methyl-N-[3-(N',N'-dimethylamino)propyl]aminosulphonyl)-1-naphthyl]-3-pyrazolecarboxylic acid.

(II: R = -SO₂N(Me)(CH₂)₃N(Me)₂; T = Me).

A solution of 0.2 g of KOH in 0.5 ml of water is added at RT to a solution of 0.82 g of the compound obtained in Preparation 3.8 in 16 ml of dioxane. The mixture is left stirring at RT for 1 day and then poured into a mixture of water and ice. The resulting mixture is washed with ether and the aqueous phase is acidified to pH 1 by adding 1N HCl. The mixture is then extracted with DCM, the organic phase is dried over sodium sulphate and the solvent is evaporated off under vacuum. 0.68 g of the expected product is obtained after crystallization in ether, m.p. = 176°C.

Preparation 4.8

1-[4-(Carbamoylmethyl)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolecarboxylic acid.

(II: R = -CH₂CONH₂; T = Me).

A mixture of the compound obtained in Preparation 3.9 and 0.35 g of KOH in 10 ml of 95 % EtOH is heated to reflux for 2 hours. The reaction mixture is evaporated under vacuum and the residue is taken up with 1N HCl solution. 1.3 g of the expected product are obtained after filtering off the precipitate formed and then drying, m.p. = 262°C.

Preparation 4.9

5-(2,6-Dimethoxyphenyl)-1-[4-[3-(N,N-dimethylamino)propoxy]-1-naphthyl]-3-pyrazolecarboxylic acid.

(II: R = -O(CH₂)₃N(Me)₂; T = Me).

A mixture of 0.25 g of the compound obtained in Preparation 3.12 and 0.025 g of lithium hydroxide monohydrate in 3 ml of MeOH and 0.4 ml of water is heated

to 60°C for 2 hours. The aqueous medium is evaporated under vacuum and neutralized to pH 7 by adding 1N HCl. 0.19 g of the expected product is obtained after filtering off the precipitate formed and then drying, and it is used in Example 16 without further treatment.

Preparation 4.10

1-[4-(Carbamoylmethoxy)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolecarboxylic acid.

(II: R = -OCH₂CONH₂; T = Me).

A mixture of 0.28 g of the compound obtained in Preparation 3.13 and 0.029 g of lithium hydroxide monohydrate in 3 ml of MeOH and 3 ml of water is heated to 60°C for 4 hours. The mixture is evaporated under vacuum, water is added and the resulting mixture is acidified to pH 2 with N HCl. 0.31 g of the expected product is obtained after filtering off the precipitate formed and then drying, m.p. = 224°C.

Preparation 4.11

5-(2,6-dimethoxyphenyl)-1-[4-{N-[3-(N',N'-dimethylamino)propyl]carbamoyl}-1-naphthyl]-3-pyrazolecarboxylic acid.

(II: R = -CONH(CH₂)₃N(Me)₂; T = Me).

A mixture of 0.5 g of the compound obtained in Preparation 3.15 and 0.058 g of lithium hydroxide monohydrate in 15 ml of MeOH and 5 ml of water is heated to reflux for 2 hours. 1N HCl solution is added to pH 6 and the mixture is concentrated under vacuum. The residue is taken up with saturated NaCl solution, DCM is added and the solid formed is drained. This solid is taken up in EtOH, some insoluble matter is filtered off and the filtrate is evaporated under vacuum. 0.41 g of the expected product is obtained.

NMR spectrum at 200 MHz in DMSO:

1.5 to 1.7 ppm : qt : 2H
2.2 ppm : s : 6H
2.4 ppm : u.c. : 2H
3.2 ppm : u.c. : 2H
3.3 ppm : s : 6H
6.4 ppm : d : 2H

6.7 ppm : s : 1H
 7.1 ppm : t : 1H
 7.2 ppm : d : 1H
 7.3 to 7.5 ppm : u.c. : 4H
 8.0 ppm : u.c. : 1H
 8.6 ppm : t : 1H

Preparation 4.12

5-(2,6-Dimethoxyphenyl)-1-[4-{N-[2-(N',N'-dimethylamino)ethyl]carbamoyl}-1-naphthyl]-3-pyrazole-carboxylic acid.

(II: R = -CONH(CH₂)₂N(Me)₂; T = Me).

A mixture of 0.6 g of the compound obtained in Preparation 3.16 and 0.088 g of lithium hydroxide monohydrate in 10 ml of MeOH and 10 ml of water is heated to 70°C for 2 hours. The mixture is concentrated under vacuum, the residue is taken up with saturated NaCl solution, 1N HCl solution is added to pH 6.5, the mixture is extracted with DCM, the organic phase is dried over Na₂SO₄ and the solvent is evaporated off under vacuum. 0.44 g of the expected product is obtained, which product is used in Example 20 without further treatment.

Preparation 4.13

1-[4-{N-(Cyanomethyl)carbamoyl}-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolecarboxylic acid.

(II: R = -CONHCH₂CN; T = Me).

A mixture of 0.77 g of the compound obtained in Preparation 3.17 and 0.118 g of lithium hydroxide monohydrate in 15 ml of MeOH and 10 ml of water is heated to reflux for 1 hour 30 minutes, and is then concentrated under vacuum. The residue is taken up with saturated NaCl solution, the mixture is extracted with DCM, the organic phase is dried over Na₂SO₄ and the solvent is evaporated off under vacuum. 0.55 g of the expected product is obtained.

NMR spectrum at 200 MHz in DMSO:

3.4 ppm : s : 6H
 3.8 ppm : s : 2H
 6.4 ppm : d : 2H
 6.8 ppm : s : 1H

7.1 ppm : t : 1H
 7.3 ppm : d : 1H
 7.4 to 7.6 ppm : u.c. : 4H
 8.2 ppm : u.c. : 1H
 8.8 ppm : u.c. : 1H

5

Preparation 4.14

1-(4-[N-(2-Cyanoethyl)-N-methylcarbamoyl]-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolecarboxylic acid.

10

(II: R = -CON(Me)CH₂CH₂CN; T = Me).

A mixture of 8 g of the compound obtained in Preparation 3.18 and 0.77 g of lithium hydroxide monohydrate in 100 ml of MeOH and 100 ml of water is left stirring overnight at RT. The reaction mixture is diluted by adding water, 1N HCl solution is then added to pH 2 and the precipitate formed is drained. After drying, 7.36 g of the expected product are obtained, m.p. = 145°C.

15

Preparation 4.15

5-(2,6-Dimethoxyphenyl)-1-[4-(N-methylcarbamoyl)-1-naphthyl]-3-pyrazolecarboxylic acid.

20

(II: R = -CONHMe; T = Me).

A mixture of the compound obtained in Preparation 3.19 and 0.69 g of lithium hydroxide monohydrate in 50 ml of MeOH and 50 ml of water is heated to 50°C for 3 hours. 10 % HCl solution is added to pH 2 and the precipitate formed is drained. After drying, the compound is recrystallized in MeOH and 3.3 g of the expected product are obtained, m.p. > 260°C.

25

NMR spectrum at 200 MHz in DMSO:

30

2.8 ppm : s : 3H
 3.4 ppm : s : 6H
 6.4 ppm : d : 2H
 6.8 ppm : s : 1H
 7.1 ppm : t : 1H
 7.35 to 8.20 ppm : u.c. : 6H
 8.45 ppm : qr : 1H

35

Preparation 4.16

5-(2,6-Dimethoxyphenyl)-1-[4-(6-acetamidohexanoylamino)-1-naphthyl]-3-pyrazolecarboxylic acid.

(II: R = -NHCO(CH₂)₅NHCOMe; T = Me).

A mixture of 0.7 g of the compound obtained in Preparation 3.20 and 0.18 g of lithium hydroxide monohydrate in 5 ml of 1,4-dioxane and 1 ml of water is left stirring overnight at RT. The mixture is concentrated under vacuum, the residue is taken up in 10 ml of MeOH and 5 ml of water and the resulting mixture is heated to 45°C for 2 hours in an ultrasonic bath. It is concentrated under vacuum, the residue is taken up in 20 ml of water, the mixture is washed with 30 ml of ether, the aqueous phase is acidified to pH 1 by adding concentrated H₂SO₄ and extracted twice with 500 ml of AcOEt, and the organic phase is dried over Na₂SO₄ and evaporated under vacuum. 0.4 g of the expected product is obtained, m.p. = 140°C.

15 Preparation 4.17

5-(2,6-Dimethoxyphenyl)-1-[4-(N-methyl-N-[3-(N',N'-dimethylamino)propyl]carbamoyl)-1-naphthyl]-3-pyrazolecarboxylic acid.

(II: R = -CON(Me)(CH₂)₃N(Me)₂; T = Me).

20 A mixture of 0.41 g of the compound obtained in Preparation 3.21 and 0.043 g of lithium hydroxide monohydrate in 15 ml of MeOH and 5 ml of water is heated at reflux for 2 hours. The mixture is concentrated under vacuum, the residue is taken up with saturated NaCl solution, 1N HCl solution is added to pH 6, the mixture is extracted with DCM, the organic phase is dried over Na₂SO₄ and the solvent is evaporated off under vacuum. 0.33 g of the expected product is obtained.

25 Preparation 4.18

30 5-(2,6-Dimethoxyphenyl)-1-[4-(N-methyl-N-[2-(N',N'-dimethylamino)ethyl]carbamoyl)-1-naphthyl]-3-pyrazolecarboxylic acid.


(II: R = -CON(Me)(CH₂)₂N(Me)₂; T = Me).

35 A mixture of 0.38 g of the compound obtained in Preparation 3.22 and 0.052 g of lithium hydroxide monohydrate in 5 ml of MeOH and 5 ml of water is heated to reflux for 2 hours. The mixture is concentrated under vacuum, the residue is taken up with saturated NaCl solution, 1N HCl solution is added to pH 6.5, the mixture

is extracted with DCM, the organic phase is dried over Na_2SO_4 and the solvent is evaporated off under vacuum. 0.32 g of the expected product is obtained.

Preparation 4.19

- 5 5-(2,6-Dimethoxyphenyl)-1-[1,3(2H)-dioxo-1H-benz[de]isoquinol-6-yl]-3-pyrazolecarboxylic acid.



- 10 A mixture of 2.4 g of the compound obtained in Preparation 3.23, 0.375 g of lithium hydroxide monohydrate, 10 ml of MeOH and 10 ml of water is left stirring overnight at RT, and is then heated for 2 hours to 60°C. After cooling, the mixture is acidified to pH 2 by adding
15 1N HCl, and the precipitate formed is drained. 2.3 g of the expected product are obtained, m.p. = 190°C (dec.).

Preparation 4.20

- 20 5-(2,6-Dimethoxyphenyl)-1-[2-amino-1,3(2H)-dioxo-1H-benz[de]isoquinol-6-yl]-3-pyrazolecarboxylic acid hydrochloride.


(II": T = Me).

- 25 A mixture of 3.3 g of the compound obtained in Preparation 3.24, 0.7 g of lithium hydroxide monohydrate, 15 ml of MeOH and 15 ml of water is left stirring overnight at RT. The reaction mixture is acidified to pH 2 by adding 1N HCl, and the precipitate formed is drained and dried. 2.76 g of the expected product are obtained, m.p. = 180°C.

30

Preparation 4.21

5-(2,6-Dimethoxyphenyl)-1-[2-acetamido-1,3(2H)-dioxo-1H-benz[de]isoquinol-6-yl]-3-pyrazolecarboxylic acid.



A mixture of 2.26 g of the compound obtained in Preparation 4.20, 1.13 ml of acetic anhydride, 0.407 g of sodium bicarbonate and 75 ml of AcOH is left stirring overnight at RT. Water is added to the reaction mixture, and the precipitate formed is drained and dried. 1.9 g of the expected product are obtained, m.p. = 250°C.

PREPARATION OF A COMPOUND III

(S)-Cyclohexylglycine methyl ester hydrochloride.

A) (S)-N-tert-Butoxycarbonylcyclohexylglycine.

A mixture of 10.7 g of (S)-N-tert-butoxycarbonylphenylglycine and 2 g of 5 % rhodium on alumina in 100 ml of MeOH is hydrogenated at RT for 4 days at 70 bars pressure. The catalyst is filtered off on Celite® and the filtrate is evaporated under vacuum. 11.1 g of the expected product are obtained.

$\alpha_D^{20} = +3.5$ [c = 1; DMF]

B) (S)-Cyclohexylglycine trifluoroacetate.

50 ml of TFA are added rapidly to a solution, cooled to 0°C, of 11 g of the compound obtained in the preceding step in 50 ml of DCM. The mixture is left stirring for 1 hour at RT and evaporated under vacuum. The residue is taken up in iso ether and the precipitate formed is filtered off. 7.6 g of the expected product are obtained, m.p. > 260°C.

$\alpha_D^{20} = +19.2$ [c = 2; HCl 5N]

C) (S)-Cyclohexylglycine methyl ester hydrochloride.

10 ml of thionyl chloride are added dropwise to a solution, cooled to -10°C , of 1.2 g of the compound obtained in the preceding step in 200 ml of MeOH. The mixture is allowed to return to RT and is heated to reflux for 2 hours. It is evaporated to dryness, the residue is taken up in toluene and the mixture is then evaporated under vacuum; this operation is repeated twice. 1 g of the expected product is obtained, m.p. $> 260^{\circ}\text{C}$.

NMR spectrum at 200 MHz in DMSO:

0.8 to 2.1 ppm : u.c. : 11H

2.6 ppm : DMSO

3.4 ppm : DHO

3.8 ppm : s : 3H

3.95 ppm : d : 1H

8.6 ppm : bs : 3H

EXAMPLE 1

20 2-[5-(2,6-Dimethoxyphenyl)-1-(4-formamido-1-naphthyl)-3-pyrazolylcarbonylamino]-2-adamantane-carboxylic acid.

(I: R = $-\text{NHCHO}$; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

25 A) 5-(2,6-Dimethoxyphenyl)-1-(4-nitro-1-naphthyl)-3-pyrazolecarbonyl chloride.

30 A solution of 14.6 g of the acid prepared in Preparation 4.1 in 100 ml of DCM and 30 ml of thionyl chloride are heated to reflux for 4 hours. The mixture is evaporated under vacuum, the residue is taken up with DCM and the mixture is evaporated again. The acid chloride thereby obtained is used in the next step without further treatment.

35 B) 2-[5-(2,6-Dimethoxyphenyl)-1-(4-nitro-1-naphthyl)-3-pyrazolylcarbonylamino]-2-adamantanecarboxylic acid.

(I': R' = $-\text{NO}_2$; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

A solution of acid chloride prepared in the preceding step in 20 ml of DCM is added at RT to a

suspension of 6.8 g of 2-amino-2-adamantanecarboxylic acid in 100 ml of DMF and 20 ml of pyridine. The mixture is left stirring overnight at RT and the solvents are evaporated off under vacuum. The residue is taken up with

5 200 ml of 1N HCl and the precipitate formed is filtered off. 10 g of the expected product are obtained after two successive recrystallizations in MeCN, m.p. = 268°C.

C) 2-[1-(4-Amino-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino]-2-adamantanecarboxylic acid.

10 (I': R' = -NH₂; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

A mixture of 0.2 g of the compound prepared in the preceding step and 0.05 g of 10 % palladium on charcoal in 200 ml of EtOH is hydrogenated at RT for 4 hours at

15 atmospheric pressure. The reaction mixture is filtered and the solvent is evaporated off under vacuum. 0.15 g of the expected product is obtained after crystallization in iso ether and recrystallization in MeOH, m.p. = 222°C.

D) 2-[5-(2,6-Dimethoxyphenyl)-1-(4-formamido-1-naphthyl)-3-pyrazolylcarbonylamino]-2-adamantanecarboxylic acid.

A mixture of 0.2 g of the compound prepared in the preceding step with 1 ml of formic acid (99-100 %; d = 1.22) in 2 ml of acetic anhydride is stirred at RT for

25 1 hour. The reaction mixture is filtered and the solid collected is washed with iso ether. 0.17 g of the expected product is obtained after drying under vacuum at 100°C, m.p. = 270°C.

EXAMPLE 2

30 2-[5-(2,6-Dimethoxyphenyl)-1-[4-(methylsulphonamido)-1-naphthyl]-3-pyrazolylcarbonylamino]-2-adamantanecarboxylic acid.

(I: R = -NHSO₂Me; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

35 A mixture of 0.3 g of the compound prepared in step C of Example 1, 0.3 g of trimethylsilyl chloride and 1.6 ml of triethylamine in 30 ml of THF is stirred at RT for 1 hour. 0.09 ml of methanesulphonyl chloride is added and the mixture is heated to reflux for 23 hours 30

minutes. It is evaporated under vacuum, the residue is extracted with DCM, and the organic phase is washed with 1N HCl and with water, dried over sodium sulphate and evaporated under vacuum. The product is chromatographed on silica, eluting with DCM and then with a DCM/MeOH (97:3; v/v to 88:12; v/v) mixture. 0.15 g of the expected product is obtained, m.p. = 200°C (dec.).

EXAMPLE 3

2-[1-(4-Acetamido-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino]-2-adamantanecarboxylic acid.

(I: R = -NHCOMe; T = Me, AA(OH) = 2-carboxy-2-adamantyl).

A) 2-[1-(4-Acetamido-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolyl]spiro[adamantane-2,4'-(2'-oxazolin-5'-one)]

A mixture of 0.2 g of the compound prepared in step C of EXAMPLE 1 with 6 ml of acetic anhydride is stirred at RT for 50 minutes. The mixture is evaporated under vacuum and the residue is taken up with 5 % aqueous sodium carbonate solution. The precipitate is filtered off, washed with water and dried in a desiccator. The product is chromatographed on silica H, eluting with a DCM/ACOEt (95:5; v/v) mixture. 0.093 g of the expected product is obtained after crystallization in iso ether, m.p. = 213°C (dec.).

B) 2-[1-(4-Acetamido-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino]-2-adamantanecarboxylic acid.

A solution of 0.09 g of the compound prepared in the preceding step in 2 ml of TFA and 2 ml of DCM is left at RT for 15 days. The solvents are evaporated off under vacuum and the residue is taken up with ether. 0.065 g of the expected product is obtained after filtration and washing with ether, m.p. = 213°C (dec.).

EXAMPLE 4

2-{5-(2,6-Dimethoxyphenyl)-1-[4-(ethanecarboxamido)-1-naphthyl]-3-pyrazolylcarbonylamino}-2-adamantanecarboxylic acid.

(I: R = -NHCOEt; T = Me; AA(OH) = 2-carboxy-2-

adamantyl).

A solution of 0.14 g of 2-amino-2-adamantanecarboxylic acid and 0.3 ml of bis(trimethylsilyl)acetamide in 7 ml of MeCN is heated to reflux for 2 hours 30 minutes under a nitrogen atmosphere. The mixture is stored at RT. Separately, 0.1 ml of isobutyl chloroformate is added to a solution, cooled to +5°C, 0.31 g of the compound prepared in Preparation 4.2 and 0.1 ml of triethylamine in 5 ml of DCM. The mixture is stirred for 3 hours at RT. This solution is poured into the above solution of the silyl derivative and left for 4 days at RT under a nitrogen atmosphere. The mixture is acidified to pH 1 by adding 1N HCl and extracted with DCM, and the organic phase is dried over sodium sulphate and evaporated under vacuum. The residue is taken up in cyclohexane under reflux and, after settling has taken place, the product is extracted with iso ether under reflux. 0.15 g of the expected product is obtained after crystallization on cooling to RT, m.p. = 192°C.

20 EXAMPLE 5

2-[1-(4-Cyano-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino]-2-adamantanecarboxylic acid.

(I: R = -CN; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

A) 1-(4-Cyano-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolecarbonyl chloride.

This compound is prepared according to the procedure described in step A of EXAMPLE 1, from 0.5 g of the compound obtained in Preparation 4.3 and 0.32 ml of thionyl chloride. 0.47 g of expected product is obtained, and it is used in the next step without further treatment.

B) 2-[1-(4-Cyano-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino]-2-adamantanecarboxylic acid.

This compound is prepared according to the procedure described in step B of EXAMPLE 1, from 0.47 g of the acid chloride of the preceding step and 0.25 g of 2-amino-2-adamantanecarboxylic acid. After evaporation under vacuum, the residue is taken up with DCM and the

precipitate formed is filtered off. The product is chromatographed on silica H, eluting with a DCM/AcOEt/AcOH (95:4.5:0.5; v/v/v) mixture. 0.152 g of the expected product is obtained after crystallization in ether, m.p. = 290°C.

EXAMPLE 6

2-{1-[4-(Hydroxyiminocarboxamido)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino}-2-adamantanecarboxylic acid.

(I: R = -C-NH₂; T = Me; AA(OH) = 2-carboxy-2-adamantyl)



A solution of 0.2 g of hydroxylamine hydrochloride in 10 ml of MeOH is added to a solution of 0.2 g of the compound prepared in EXAMPLE 5 in 20 ml of EtOH; a solution of 0.2 g of potassium carbonate in 4 ml of water is then introduced. The reaction mixture is heated to reflux for 2 days and then partially concentrated under vacuum. 0.15 g of the expected product is obtained after adding water and filtering off the precipitate formed, m.p. = 230°C.

EXAMPLE 7

2-[1-(4-Carbamoyl-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino]-2-adamantanecarboxylic acid.

(I: R = -CONH₂; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

A mixture of 0.2 g of the compound prepared in EXAMPLE 5, 0.4 ml of hydrogen peroxide (33 % aqueous solution) and 0.4 ml of 6N NaOH in 25 ml of 95 % EtOH is heated to reflux for 2 days. 0.4 ml of hydrogen peroxide and 0.4 ml of 6N NaOH are then added to the reaction mixture and refluxing is continued for 1 day. After filtration, the filtrate is diluted with water and extracted with DCM. The aqueous phase is acidified to pH 2 by adding concentrated HCl. The precipitate formed is filtered off and washed with water. 0.128 g of the expected product is obtained after crystallization, m.p. = 287°C.

The compound of EXAMPLE 7 may also be obtained according to the process described below.

2-[1-(4-Carbamoyl-1-naphthyl)-5-(2,6-dimethoxy-phenyl)-3-pyrazolylcarbonylamino]-2-adamantanecarboxylic acid.

This compound is prepared according to the procedure described in EXAMPLE 4, from 0.45 g of the compound obtained in Preparation 4.4 and 0.22 g of 2-amino-2-adamantanecarboxylic acid. The compound is purified by chromatography on silica, eluting with a DCM/MeOH/AcOH (100:4:0.5; v/v/v) mixture followed by crystallization in ether. 0.3 g of the expected product is obtained, m.p. = 292°C.

EXAMPLE 8

Sodium 2-[1-(4-carbamoyl-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino]-2-adamantane-carboxylate.

(I: R = -CONH₂; T = Me; AA(OH) = 2-carboxy-2-adamantyl, sodium salt).

0.05 g of the compound prepared in EXAMPLE 7 is added to a solution of 0.005 g of sodium carbonate in 0.3 ml of water and 3 ml of MeOH. The mixture is left for 48 hours at -18°C. After evaporation to dryness under vacuum, the residue is triturated in 3 ml of 2-propanol. 0.04 g of the expected product is obtained after filtration and drying under vacuum over P₂O₅, m.p. = 335°C (dec.).

EXAMPLE 9

N-Methyl-D-glucamine 2-[1-(4-carbamoyl-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino]-2-adamantanecarboxylate.

(I: R = -CONH₂; T = Me; AA(OH) = 2-carboxy-2-adamantyl, N-methyl-D-glucamine salt).

0.05 g of the compound prepared in EXAMPLE 7 is added to a solution of 0.017 g of N-methyl-D-glucamine in 4 ml of MeOH; 8 ml of ether are then added. The mixture is left for 3 days at -18°C. 0.04 g of the expected product is obtained after filtering off the crystals formed and drying under vacuum over P₂O₅, m.p. = 170-172°C.

EXAMPLE 10

(2S)-2-[1-(4-Carbamoyl-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino]-2-cyclohexylacetic acid.

(I: R = -CONH₂; T = Me; AA(OH) = α-carboxycyclohexylmethyl).

A) (2S)-2-[1-(4-Carbamoyl-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino]-2-cyclohexylacetic acid methyl ester.

(I: R = -CONH₂; T = Me; AA(OH) = α-carboxycyclohexylmethyl methyl ester).

A mixture of 0.45 g of the compound obtained in Preparation 4.4, 0.15 ml of triethylamine and 0.15 ml of isobutyl chloroformate in 10 ml of DCM is stirred at RT for 1 hour 30 minutes under a nitrogen atmosphere. A solution of 0.224 g of (S)-cyclohexylglycine methyl ester hydrochloride and 0.15 ml of triethylamine in 5 ml of DCM is then added slowly. The mixture is left stirring for 5 days at RT. After filtering off some insoluble matter, the filtrate is washed with 1N HCl solution, dried over sodium sulphate and evaporated under vacuum. 0.37 g of the expected product is obtained after recrystallization in MeCN, m.p. = 198°C.

B) (2S)-2-[1-(4-Carbamoyl-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino]-2-cyclohexylacetic acid.

A solution of 0.081 g of KOH in 1 ml of water is added at RT to a solution of 0.33 g of the compound obtained in the preceding step in 5 ml of dioxane, and the reaction mixture is left stirring for 5 hours at RT. It is then evaporated under vacuum and the residue is taken up with water. It is acidified to pH 1 by adding 1N HCl solution. 0.28 g of the expected product is obtained after filtration, washing with water and drying, m.p. = 186°C. α_D = +4° (c = 0.5; EtOH).

EXAMPLE 11

2-[1-[4-(Acetylaminomethyl)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino]-2-adamantanecarboxylic acid.

(I: R = -CH₂NHCOMe; T = Me; AA(OH) = 2-carboxy-2-

adamantyl).

A) 1-[4-(Acetylaminoethyl)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolecarbonyl chloride.

This compound is prepared according to the procedure described in step A of EXAMPLE 1, from 0.55 g of the compound obtained in Preparation 4.5 and 0.31 ml of thionyl chloride. The product obtained is used in the next step without further treatment.

B) 2-{1-[4-(Acetylaminoethyl)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino}-2-adamantanecarboxylic acid.

A solution of the acid chloride prepared in the preceding step in 7 ml of DCM is added at RT under a nitrogen atmosphere to a mixture of 0.29 g of 2-amino-2-adamantanecarboxylic acid and 15 ml of pyridine. The resulting mixture is left stirring for 72 hours at RT. Some insoluble matter is then filtered off and the filtrate is evaporated under vacuum. The residue is extracted with DCM, the organic phase is washed with a pH 2 buffer and dried over sodium sulphate and the solvent is evaporated off under vacuum. The product is then chromatographed on silica H, eluting with a DCM/MeOH (100:4; v/v) mixture. 0.15 g of the expected product is obtained after crystallization in ether, m.p. = 211°C.

EXAMPLE 12

2-{5-(2,6-Dimethoxyphenyl)-1-[4-(dimethylamino)sulphonyl]-1-naphthyl]-3-pyrazolylcarbonylamino}-2-adamantanecarboxylic acid.

(I: R = -SO₂N(Me)₂; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

A) 5-(2,6-Dimethoxyphenyl)-1-[4-(dimethylamino)sulphonyl]-1-naphthyl]-3-pyrazolecarbonyl chloride.

This compound is prepared according to the procedure described in step A of EXAMPLE 1, from 1.46 g of the compound obtained in Preparation 4.6 and 0.77 ml of thionyl chloride. The product obtained is used immediately in the next step.

B) 2-{5-(2,6-Dimethoxyphenyl)-1-[4-(dimethylamino)sulphonyl]-1-naphthyl]-3-pyrazolylcarbonylamino}-2-

adamantanecarboxylic acid.

This compound is prepared according to the procedure described in step B of EXAMPLE 11, from the compound obtained in the preceding step and 0.7 g of 2-amino-2-adamantanecarboxylic acid. The product is purified by chromatography on silica H, eluting with a DCM/ACOEt/ACOH (90:10:0.5; v/v/v) mixture. 0.6 g of the expected product is obtained after crystallization in hexane, m.p. = 269°C.

EXAMPLE 13

2-(5-(2,6-dimethoxyphenyl)-1-[4-(N-methyl-N-[3-(N',N'-dimethylamino)propyl]aminosulphonyl)-1-naphthyl]-3-pyrazolylcarbonylamino)-2-adamantane-carboxylic acid hydrochloride.

(I: R = -SO₂N(Me)(CH₂)₃N(Me)₂; T = Me; AA (OH) = 2-carboxy-2-adamantyl).

This compound is prepared according to the procedure described in EXAMPLE 4 from 0.37 g of the compound obtained in Preparation 4.7 and 0.13 g of 2-amino-2-adamantanecarboxylic acid. The product is purified by chromatography on silica H, eluting with a DCM/MeOH/ACOH (100:8:1; v/v/v) mixture. 0.11 g of the expected product is obtained after crystallization in ether, m.p. = 246°C (dec.).

The compound of EXAMPLE 13 may also be obtained according to the 2 steps of the process described below.

A') 5-(2,6-Dimethoxyphenyl)-1-[4-(N-methyl-N-[3-(N',N'-dimethylamino)propyl]aminosulphonyl)-1-naphthyl]-3-pyrazolecarbonyl chloride.

A mixture of 0.2 g of the compound obtained in Preparation 4.7 and 2 ml of thionyl chloride is stirred for 3 hours under a nitrogen atmosphere at RT. A further 2 ml of thionyl chloride are then added and stirring is continued at RT for 1 hour 30 minutes. The reaction mixture is evaporated under vacuum, the residue is taken up with DCM and the mixture is evaporated again under vacuum. The acid chloride thereby obtained is used in the next step without further treatment.

B') 2-(5-(2,6-Dimethoxyphenyl)-1-[4-(N-methyl-N-[3-

(N',N'-dimethylamino)propyl]aminosulphonyl]-1-naphthyl]-3-pyrazolylcarbonylamino)-2-adamantanecarboxylic acid.

A mixture of 0.071 g of 2-amino-2-adamantanecarboxylic acid and 0.36 ml of bis(trimethylsilyl)-acetamide in 10 ml of MeCN is heated to reflux for 15 minutes under a nitrogen atmosphere. After cooling, a solution of the acid chloride obtained in the preceding step in 10 ml of DCM is added and the mixture is left stirring for 48 hours at RT. Water is added, the mixture is acidified to pH 2 by adding 1.2N HCl and extracted with DCM, and the organic phase is dried over sodium sulphate and evaporated under vacuum. 0.23 g of the expected product is obtained.

EXAMPLE 14

2-{1-[4-(Carbamoylmethyl)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino}-2-adamantanecarboxylic acid.

(I: R = -CH₂CONH₂; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

This compound is prepared according to the procedure described in EXAMPLE 4, from 0.8 g of the compound obtained in Preparation 4.8 and 0.4 g of 2-amino-2-adamantanecarboxylic acid. After evaporation of the reaction mixture, 1N HCl solution and EtOH are added to the residue. After stirring, the precipitate formed is filtered off and dried under vacuum. The product is then chromatographed on silica H, eluting with a DCM/MeOH/AcOH (100:4:0.5; v/v/v) mixture. The product obtained is dissolved in a solution of 1N NaOH and EtOH, the mixture is acidified to pH 1 by adding 1N HCl and extracted with DCM, the organic phase is dried over sodium sulphate and the solvent is evaporated off under vacuum. 0.53 g of the expected product is obtained after crystallization in EtOH, m.p. = 224°C.

EXAMPLE 15

2-{1-[4-(Carboxymethyl)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino}-2-adamantanecarboxylic acid.

(I: R = -CH₂CO₂H; T = Me; AA(OH) = 2-carboxy-2-

adamantyl).

A mixture of 0.17 g of the compound obtained in EXAMPLE 14 and 0.135 g of sodium peroxide in 5 ml of water and a few drops of MeOH is heated to 60°C for 1 day. The mixture is acidified to pH 1 by adding 1N HCl and left stirring. After filtration, the expected product is obtained by crystallization in MeCN, m = 0.1 g, m.p. = 267°C.

EXAMPLE 16

2-[5-(2,6-Dimethoxyphenyl)-1-{4-[3-(N,N-dimethylamino)propoxy]-1-naphthyl}-3-pyrazolylcarbonylamino]-2-adamantanecarboxylic acid.

(I: R = -O(CH₂)₃N(Me)₂; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

This compound is prepared according to the procedure described in EXAMPLE 4, from 0.19 g of the compound obtained in Preparation 4.9 and 0.14 g of 2-amino-2-adamantanecarboxylic acid. The compound is purified by chromatography on silica, eluting with a DCM/MeOH/NH₄OH (100:15:1; v/v/v) mixture. 0.04 g of the expected product is obtained, m.p. = 200°C.

EXAMPLE 17

2-{1-[4-(Carbamoylmethoxy)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino}-2-adamantanecarboxylic acid.

(I: R = -OCH₂CONH₂; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

This compound is prepared according to the procedure described in EXAMPLE 4, from 0.31 g of the compound obtained in Preparation 4.10 and 0.27 g of 2-amino-2-adamantanecarboxylic acid. The compound is purified by chromatography on silica H, eluting with a DCM/MeOH/AcOH (100:1:0.5; v/v/v) mixture. 0.14 g of expected product is obtained, m.p. = 200°C.

EXAMPLE 18

2-[5-(2,6-Dimethoxyphenyl)-1-[4-{N-[3-(N',N'-dimethylamino)propyl]carbamoyl}-1-naphthyl]-3-pyrazolylcarbonylamino]-2-adamantanecarboxylic acid.

(I: R = -CONH(CH₂)₃N(Me)₂; T = Me; AA(OH) = 2-

carboxy-2-adamantyl).

A mixture of 2 g of the compound obtained in Preparation 4.11 and 10 ml of thionyl chloride in 30 ml of DCM is heated to 35°C for 1 hour. The mixture is concentrated under vacuum and the acid chloride thereby obtained is used without further treatment. Separately, a mixture of 1.2 g of 2-amino-2-adamantanecarboxylic acid and 3 ml of bis(trimethylsilyl)acetamide in 70 ml of MeCN is heated to reflux for 1 hour. After cooling to RT, a solution of the acid chloride prepared above in 50 ml of DCM is added, followed by 0.57 ml of triethylamine, and the reaction mixture is left stirring for 48 hours at RT. It is concentrated under vacuum, the residue is taken up with water, the mixture is acidified to pH 2 by adding 1N HCl and left stirring for 1 hour, and the precipitate formed is drained. The precipitate is dissolved in hot water, 5 % NaOH solution is added to pH 6, the mixture is extracted with DCM, the organic phase is dried over Na₂SO₄ and the solvent is evaporated off under vacuum. 0.48 g of the expected product is obtained after crystallization in 2-propanol and recrystallization in MeOH, m.p. = 244°C.

NMR spectrum at 200 MHz in DMSO:

1.4 to 2.1 ppm : u.c. : 14H
 2.2 ppm : s : 6H
 2.4 ppm : t : 2H
 2.55 ppm : u.c. : 2H
 3.4 ppm : qr : 2H
 3.6 ppm : s : 6H
 6.5 ppm : d : 2H
 6.9 ppm : s : 1H
 7.2 ppm : t : 1H
 7.4 to 7.8 ppm : u.c. : 6H
 8.2 ppm : u.c. : 1H
 8.7 ppm : t : 1H

EXAMPLE 19

2-(5-(2,6-Dimethoxyphenyl)-1-[4-{N-[3-(N',N'-dimethylamino)propyl]carbonyl}-1-naphthyl]-3-pyrazol-ylcarbonylamino)-2-adamantanecarboxylic acid p-toluene-sulphonate.

0.130 ml of isobutyl chloroformate is added to a solution, cooled to +5°C, of 0.4 g of the compound obtained in Preparation 4.11 and 0.127 ml of triethylamine in 10 ml of DCM, and the mixture is left stirring for 2 days at RT. Separately, a mixture of 0.231 g of 2-amino-2-adamantanecarboxylic acid and 0.87 ml of bis(trimethylsilyl)acetamide in 15 ml of MeCN is heated to reflux for 1 hour 30 minutes. After cooling to RT, the solution of mixed anhydride prepared above is added and the mixture is left stirring for 2 days at RT. Water is added to the reaction mixture, which is acidified to pH 2 by adding 1N HCl, left stirring and concentrated under vacuum. The residue is taken up with water, 5 % NaOH solution is added to pH 6.5, the mixture is extracted with DCM, some insoluble matter is filtered off, the filtrate is dried over Na₂SO₄ and the solvent is evaporated off under vacuum. 0.23 g of crude product is obtained. 0.11 g of the product thereby obtained is dissolved in a minimum of MeCN, 0.032 g of p-toluenesulphonic acid monohydrate is added and ether is added until precipitation occurs. 0.050 g of the expected product is obtained after draining and drying.

NMR spectrum at 200 MHz in DMSO:

1.6 to 2.2 ppm : u.c. : 14H
 2.4 ppm : s : 3H
 2.5 ppm : u.c. : 2H
 2.9 ppm : s : 6H
 3.2 ppm : t : 2H
 3.3 to 3.8 ppm : u.c. : 8H
 6.5 ppm : d : 2H
 6.9 ppm : s : 1H
 7.2 ppm : d : 3H
 7.4 to 7.8 ppm : u.c. : 7H
 8.2 ppm : u.c. : 1H
 8.7 ppm : t : 1H

EXAMPLE 20

2-{5-(2,6-Dimethoxyphenyl)-1-[4-(N-[2-(N',N'-dimethylamino)ethyl]carbamoyl)-1-naphthyl]-3-pyrazolyl-carbonylamino}-2-adamantanecarboxylic acid.

(I: R = $-\text{CONH}(\text{CH}_2)_2\text{N}(\text{Me})_2$; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

A mixture of 2 g of the compound obtained in Preparation 4.12 and 10 ml of thionyl chloride in 30 ml of DCM is heated to 35°C for 1 hour. The mixture is concentrated under vacuum and the acid chloride thereby obtained is used without further treatment. Separately, a mixture of 1.2 g of 2-amino-2-adamantanecarboxylic acid and 3 ml of bis(trimethylsilyl)acetamide in 70 ml of MeCN is heated at reflux for 1 hour. After cooling to RT, a solution of the acid chloride prepared above in 50 ml of DCM is added, followed by 0.58 ml of triethylamine, and the reaction mixture is left stirring overnight at RT. It is concentrated under vacuum, the residue is taken up with water (crystallization of the product), and the mixture is acidified to pH 2 by adding 1N HCl and left stirring for 1 hour. The crystallized product is drained and, after drying, it is chromatographed on silica H, eluting with a gradient of a DCM/MeOH/H₂O (100:5:0.2; v/v/v to 100:10:0.75; v/v/v) mixture. 0.62 g of the expected product is obtained after crystallization in acetone.

NMR spectrum at 200 MHz in DMSO:

1.4 to 2.2 ppm : u.c. : 12H

2.6 ppm : u.c. : 2H

2.8 ppm : s : 6H

3.3 ppm : t : 2H

3.45 ppm : s : 6H

3.7 ppm : t : 2H

6.4 ppm : d : 2H

6.9 ppm : s : 1H

7.2 ppm : t : 1H

7.4 ppm : d : 1H

7.6 ppm : u.c. : 3H

7.7 ppm : d : 1H

8.2 ppm : u.c. : 1H

8.4 ppm : t : 1H

This compound is also prepared according to the procedure described below.

0.139 ml of isobutyl chloroformate is added to a

solution, cooled to +5°C, of 0.44 g of the compound obtained in Preparation 4.12 and 0.140 ml of triethylamine in 10 ml of DCM, and the mixture is left stirring for 3 days at RT.

5 Separately, a mixture of 0.321 g of 2-amino-2-adamantanecarboxylic acid and 0.49 ml of bis(trimethylsilyl)acetamide in 20 ml of MeCN is heated to reflux for 1 hour 30 minutes. After cooling to RT, the solution of mixed anhydride prepared above is added and
10 the mixture is left stirring for 3 days at RT. 1N HCl solution is added to pH 2, followed by MeOH, and the mixture is concentrated under vacuum. The residue is taken up with saturated NaCl solution, the mixture is extracted with DCM, the organic phase is dried over Na₂SO₄ and the
15 solvent is evaporated off under vacuum. The residue is taken up with water, aqueous ammonia solution is added to pH 7-8, and the precipitate formed is drained and dried. The precipitate is chromatographed on silica H, eluting with a DCM/MeOH/H₂O (80:10:0.75; v/v/v) mixture and then
20 with a DCM/MeOH/H₂O (80:15:2; v/v/v) mixture. 0.04 g of the expected product is obtained.

EXAMPLE 21

2-[1-(4-[N-(Cyanomethyl)carbamoyl]-1-naphthyl)-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino]-2-
25 adamantanecarboxylic acid.

(I: R = -CONHCH₂CN; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

0.181 ml of isobutyl chloroformate is added to a solution of 0.55 g of the compound obtained in Preparation
30 4.13 and 0.176 ml of triethylamine in 10 ml of 1,4-dioxane, and the mixture is left stirring for 6 days at RT. Separately, a mixture of 0.351 g of 2-amino-2-adamantanecarboxylic acid and 0.106 ml of bis-(trimethylsilyl)acetamide in 20 ml of MeCN is heated to
35 reflux for 1 hour 30 minutes. After cooling to RT, the solution of mixed anhydride prepared above is added and the mixture is left stirring for 3 days at RT. 1N HCl solution is then added to pH 2 and the mixture is left stirring for 2 hours at RT. It is concentrated under

vacuum, the residue is taken up with saturated NaCl solution, the mixture is extracted with DCM and some insoluble matter is filtered off. After settling has taken place, the organic phase is dried over Na₂SO₄ and the solvent is evaporated off under vacuum. The residue is chromatographed on silica H, eluting with a DCM/MeOH/H₂O (80:5:0.3; v/v/v) mixture. 0.080 g of the expected product is obtained.

NMR spectrum at 200 MHz in DMSO:

1.4 to 2.3 ppm : u.c. : 12H
 2.6 ppm : u.c. : 2H
 3.5 ppm : s : 6H
 4.0 ppm : s : 2H
 6.4 ppm : d : 2H
 6.9 ppm : s : 1H
 7.2 ppm : t : 1H
 7.4 to 7.8 ppm : u.c. : 5H
 8.4 ppm : u.c. : 1H
 8.8 ppm : t : 1H

20 EXAMPLE 22

2-[1-{4-[N-(2-Cyanoethyl)-N-methylcarbamoyl]-1-naphthyl}-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonyl-amino]-2-adamantanecarboxylic acid.

(I: R = -CON(Me)CH₂CH₂CN; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

A mixture of 4 g of the compound obtained in Preparation 4.14 and 40 ml of thionyl chloride in 40 ml of DCM is heated to 35°C for 2 hours. The mixture is concentrated under vacuum and the acid chloride thereby obtained is used without further treatment. Separately, a mixture of 2.34 g of 2-amino-2-adamantanecarboxylic acid and 6 ml of bis(trimethylsilyl)acetamide in 150 ml of MeCN is heated to reflux for 1 hour. After cooling to RT, a solution of the acid chloride prepared above in 100 ml of DCM is added, followed by 1.12 ml of triethylamine, and the mixture is left stirring overnight at RT. It is concentrated under vacuum, the residue is taken up with water, 1N HCl solution is added to pH 2, the mixture is left stirring and the solid formed is drained. After

drying, the solid is chromatographed on silica H, eluting with a DCM/MeOH/H₂O (100:10:1; v/v/v) mixture. The expected product is obtained after crystallization in acetone, m.p. = 264°C.

5 EXAMPLE 23

2-{5-(2,6-dimethoxyphenyl)-1-[4-(N-methyl-N-[2-(N¹-methyl-N²-methyamidino)ethyl]carbamoyl)-1-naphthyl]-3-pyrazolylcarbonylamino}-2-adamantane-carboxylic acid.

10 (I: R = -CON(Me)CH₂CH₂C(=NMe)NHMe; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

1 g of the compound obtained in EXAMPLE 22 is dissolved in 30 ml of EtOH and 10 ml of ether, and gaseous HCl is then bubbled through for 2 hours. The mixture is left overnight at +5°C and concentrated under vacuum. The residue is taken up in 50 ml of EtOH and gaseous methylamine is bubbled through for 2 hours at RT. The mixture is concentrated under vacuum, the residue is taken up in an EtOH/ether mixture, the methylamine hydrochloride which has crystallized is filtered off and the filtrate is evaporated under vacuum. The residue is taken up with water, and the crystals formed are drained and dried. 0.7 g of the expected product is obtained after recrystallization in EtOH, m.p. = 235°C.

25 NMR spectrum at 200 MHz in DMSO:

1.4 to 2.4 ppm : u.c. : 12H

2.5 to 4.0 ppm : u.c. : 21H

6.5 ppm : d : 2H

6.9 ppm : s : 1H

30 7.15 ppm : t : 1H

7.3 to 7.8 ppm : u.c. : 6H

EXAMPLE 24

2-{5-(2,6-Dimethoxyphenyl)-1-[4-(N¹-methyl-N²-methyamidino)-1-naphthyl]-3-pyrazolylcarbonylamino}-2-adamantanecarboxylic acid.

35

(I: R = -C(=NMe)NHMe; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

A) 2-{5-(2,6-Dimethoxyphenyl)-1-[4-(N-methylcarbamoyl)-1-naphthyl]-3-pyrazolylcarbonylamino}-2-adamantane-

carboxylic acid.

This compound is prepared according to the procedure described in EXAMPLE 22, from 2 g of the compound obtained in Preparation 4.15, 25 ml of thionyl chloride and then 1.39 g of 2-amino-2-adamantanecarboxylic acid, 3.5 ml of bis(trimethylsilyl)acetamide and 0.64 ml of triethylamine. The product is chromatographed on silica H, eluting with a DCM/MeOH/H₂O (100:3:0.2; v/v/v, then 100/5/0.4; v/v/v) mixture. 1.2 g of the expected product are obtained, m.p. = 170°C.

B) 2-{5-(2,6-Dimethoxyphenyl)-1-[4-(N¹-methyl-N²-methylamidino)-1-naphthyl]-3-pyrazolylcarbonylamino}-2-adamantanecarboxylic acid.

A mixture of 0.5 g of the compound obtained in the preceding step and 0.34 g of phosphorus pentachloride in 15 ml of toluene is heated to reflux for 20 minutes. After cooling, the solid crystallized is drained, the crystals are taken up in 30 ml of EtOH and gaseous methylamine is bubbled into the solution. The mixture is concentrated under vacuum and the residue is chromatographed on silica H, eluting with a DCM/MeOH/H₂O (100:2:0.2; v/v/v) mixture. 0.18 g of the expected product is obtained, m.p. = 180°C.

EXAMPLE 25

25 2-{1-[4-(2,6-Acetamidohexanoylamino)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino}-2-adamantanecarboxylic acid.

(I: R = -NHCO(CH₂)₅NHCOMe; T = Me; AA(OH) = 2-carboxy-2-adamanty).

0.12 ml of isobutyl chloroformate is added to a solution, cooled to 5°C, of 0.4 g of the compound obtained in Preparation 4.16 and 0.2 ml of triethylamine in 5 ml of MeCN, and the mixture is left stirring for 2 hours at RT. Separately, a mixture of 0.21 g of 2-amino-2-adamantanecarboxylic acid and 2 ml of bis(trimethylsilyl)acetamide in 3 ml of MeCN is left stirring for 2 hours at RT. This solution is then added to the solution of mixed anhydride prepared above, and the mixture is left stirring for 16 days at RT. 5 ml of MeOH

and 1 ml of water are then added to the reaction mixture, which is left stirring for 30 minutes and concentrated under vacuum. The residue is taken up in 100 ml of DCM, some insoluble matter is filtered off, the filtrate is washed with water and with 1N HCl solution, and the organic phase is dried over Na₂SO₄ and evaporated under vacuum. The residue is chromatographed on silica H, eluting with a DCM/MeOH/AcOH (100:8:1; v/v/v) mixture. 0.07 g of the expected product is obtained after crystallization in ether, m.p. = 190°C.

EXAMPLE 26

2-{1-[4-(2-Aminoethyl)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino}-2-adamantanecarboxylic acid.

(I: R = -CH₂CH₂NH₂; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

A) 2-{1-[4-(Cyanomethyl)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino}-2-adamantanecarboxylic acid.

A mixture of 5 g of the compound obtained in Preparation 4.8 and 50 ml of thionyl chloride in 125 ml of DCM is heated to 40°C for 1 hour and then concentrated under vacuum. Separately, a mixture of 3.38 g of 2-amino-2-adamantanecarboxylic acid and 8.75 ml of bis-(trimethylsilyl)acetamide in 150 ml of MeCN is heated to reflux for 1 hour. After cooling to RT, a solution of the acid chloride prepared above in 100 ml of DCM is added, followed by 1.6 ml of triethylamine, and the mixture is left stirring overnight at RT. It is concentrated under vacuum, the residue is dissolved in EtOH and ether is added until crystallization occurs. After draining of the crystals (compound of EXAMPLE 14), the filtrate is concentrated under vacuum. The residue is taken up in EtOH, 3N HCl solution is added to pH 1, and the precipitate formed is drained and dried. The precipitate is chromatographed on silica H, eluting with a DCM/MeOH/AcOH (100:3:0.5; v/v/v) mixture. The compound of EXAMPLE 14 is separated and 1.2 g of the expected product are then obtained.

B) 2-{1-[4-(2-Aminoethyl)-1-naphthyl]-5-(2,6-dimethoxyphenyl)-3-pyrazolylcarbonylamino}-2-adamantane-carboxylic acid.

A mixture of 1.2 g of the compound obtained in the preceding step, 0.12 g of Raney® nickel, 60 ml of MeOH and 10 ml of concentrated aqueous ammonia is hydrogenated at RT and at atmospheric pressure. The catalyst is filtered off and the filtrate is partially concentrated under vacuum. The crystals formed are drained and dried. 0.89 g of the expected product is obtained, m.p. = 250°C.

NMR spectrum at 200 MHz in DMSO:

1.4 to 2.2 ppm : u.c. : 12H
 2.5 ppm : u.c. : 2H
 3.0 to 3.6 ppm : u.c. : 10H
 6.4 ppm : d : 2H
 6.9 ppm : s : 1H
 7.1 ppm : t : 1H
 7.2 to 7.6 ppm : u.c. : 5H
 8.1 ppm : u.c. : 1H

EXAMPLE 27

2-{5-(2,6-Dimethoxyphenyl)-1-[4-{N-methyl-N-[3-(N',N'-dimethylamino)propyl]carbamoyl}-1-naphthyl]-3-pyrazolylcarbonylamino}-2-adamantanecarboxylic acid hydrochloride.

(I: R = -CON(Me)(CH₂)₃N(Me)₂; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

This compound is prepared according to the procedure described in EXAMPLE 18, from 0.32 g of the compound obtained in Preparation 4.17, 2 ml of thionyl chloride, 5 ml of DCM and then 0.185 g of 2-amino-2-adamantanecarboxylic acid, 0.465 ml of bis(trimethylsilyl)acetamide, 10 ml of MeCN and 0.09 ml of triethylamine. The crude product is dissolved in a minimum of EtOH, a saturated solution of HCl in ether is added and the mixture is concentrated under vacuum. 0.1 g of the expected product is obtained after crystallization in ether.

EXAMPLE 28

2-{5-(2,6-Dimethoxyphenyl)-1-[4-{N-methyl-N-[2-


(N',N'-dimethylamino)ethyl]carbonyl}-1-naphthyl]-3-pyrazolylcarbonylamino)-2-adamantanecarboxylic acid hydrochloride.

(I: R = -CON(Me)(CH₂)₂N(Me)₂; T = Me; AA(OH) = 2-carboxy-2-adamantyl).

This compound is prepared according to the procedure described in EXAMPLE 18, from 0.31 g of the compound obtained in Preparation 4.18, 2 ml of thionyl chloride, 5 ml of DCM and then 0.185 g of 2-amino-2-adamantanecarboxylic acid, 0.465 ml of bis(trimethylsilyl)acetamide, 10 ml of MeCN and 0.09 ml of triethylamine. The crude product is dissolved in a minimum of EtOH, a saturated solution of HCl in ether is added and the mixture is concentrated under vacuum. 0.08 g of the expected product is obtained after crystallization in ether.

EXAMPLE 29

2-{5-(2,6-Dimethoxyphenyl)-1-[1,3(2H)-dioxo-1H-benz[de]isoquinol-6-yl]-3-pyrazolylcarbonylamino}-2-adamantanecarboxylic acid




0.43 ml of isobutyl chloroformate is added to a solution, cooled to 5°C, of 1.4 g of the compound obtained in Preparation 4.19 and 0.28 ml of pyridine in 20 ml of MeCN, and the mixture is left stirring for 1 hour at RT. Separately, a mixture of 0.64 g of 2-amino-2-adamantanecarboxylic acid and 1.54 ml of bis(trimethylsilyl)acetamide in 30 ml of MeCN is heated to reflux for 1 hour. After cooling to RT, the solution of mixed anhydride prepared above is added, and the reaction mixture is left stirring for three days at RT and under a nitrogen atmosphere. It is acidified to pH 2 by adding 1N HCl and concentrated under vacuum. The residue is taken up with water, the mixture is extracted with AcOEt, the

organic phase is dried over Na_2SO_4 and the solvent is evaporated off under vacuum. The residue is chromatographed on silica H, eluting with a DCM/MeOH/AcOH (100:1:0.5; v/v/v) mixture. The product obtained is taken up in MeOH, and the mixture is alkalized by adding concentrated NaOH and concentrated under vacuum. The product is taken up in the form of a sodium salt in MeOH, the mixture is acidified to pH 1 by adding 1N HCl and the precipitate formed is drained. 0.17 g of the expected product is obtained, m.p. = 210°C.

EXAMPLE 30


2-{5-(2,6-Dimethoxyphenyl)-1-[2-acetamido-1,3(2H)-dioxo-1H-benz[de]isoquinol-6-yl]-3-pyrazolyl-carbonylamino}-2-adamantanecarboxylic acid



This compound is prepared according to the procedure described in EXAMPLE 29, from 0.9 g of the compound obtained in Preparation 4.21, 0.25 ml of triethylamine, 0.25 ml of isobutyl chloroformate and 15 ml of DCM, and then 0.36 g of 2-amino-2-adamantanecarboxylic acid, 0.89 ml of bis(trimethylsilyl)acetamide and 20 ml of MeCN. The crude product is chromatographed on silica H, eluting with a DCM/MeOH/AcOH (100:3:0.5; v/v/v) mixture. The product obtained is dissolved in 1N NaOH, the mixture is acidified to pH 3 by adding 1N HCl and extracted with AcOEt, the organic phase is dried over Na_2SO_4 and the solvent is evaporated off under vacuum. 0.45 g of the expected product is obtained after crystallization in ether, m.p. = 292°C.

Using the procedure described in EXAMPLE 7 (2nd process), and starting from the compound obtained in Preparation 4.4, the compounds according to the invention collated in TABLE 1 below are prepared.


TABLE 1



EXAMPLES	-NH-AA(OH)
31	
32	
33	
34	

Using the procedure described in EXAMPLE 10, and starting from the compound obtained in Preparation 4.4, the compounds according to the invention collated in TABLE 2 below are prepared.

TABLE 2



EXAMPLES	-NH-AA(OH)
35	$\begin{array}{c} \text{CH}_2\text{-CH}(\text{CH}_3)_2 \\ \\ \text{-HN-CH-COOH} \end{array}$
36	$\begin{array}{c} (\text{CH}_2)_3\text{-CH}_3 \\ \\ \text{-HN-CH-COOH} \end{array}$
37	$\begin{array}{c} \text{CH}(\text{CH}_3)_2 \\ \\ \text{-HN-CH-COOH} \end{array}$
38	$\begin{array}{c} \text{[Bicyclic structure: 1,2,3,4,5,6-hexahydro-1,2,4-triazolo[4,5-c]pyridine-5-carboxylic acid derivative]} \\ \\ \text{-HN-CH-COOH} \end{array}$
39	$\begin{array}{c} \text{[Bicyclic structure: 1,2,3,4,5,6,7,8-octahydro-1,2,4-triazolo[4,5-c]pyridine-5-carboxylic acid derivative]} \\ \\ \text{-HN-CH-COOH} \end{array}$


EXAMPLE 40

2-(5-(2,6-dimethoxyphenyl)-1-[4-[N-(3-(N',N'-
dimethylamino)propyl]carbonyl]napht-1-yl]pyrazol-3-
5 ylcarbonylamino)adamantane-2-carboxylic acid
hydrochloride.

- This compound is prepared according to the procedure described in Example 18, from 5.6g of the compound obtained in Preparation 4.11, 20ml of oxalyl chloride and 20ml of DCM and then 3.4g of 2-aminoadamantane-2-carboxylic acid, 8.4ml of MeCN and 1.6ml of triethylamine. 1.3g of the expected product is obtained under the form of a base after crystallization in propan-2-ol and recrystallization in MeOH(m.p. = 242°C). 20mg of the product so obtained is dissolved in a minimum of MeOH, acidified to pH1 by adding a ether solution saturated with HCl and concentrated under vacuum. The expected hydrochloride is obtained after crystallization in a acetone/pentane mixture ; m.p. = 200°C (decomposition).
- 20 NMR spectrum at 200 MHz in DMSO :
- 0.4 to 2.3 ppm : u.c. : 14 H
 - 2.6 ppm : bs : 2 H
 - 2.8 ppm : bs : 6 H
 - 3.15 ppm : bs : 2 H
 - 25 3.4 ppm : bs : 2 H
 - 3.55 ppm : s : 6 H
 - 6.5 ppm : d : 2 H
 - 6.9 ppm : s : 1 H
 - 7.2 ppm : t : 1 H
 - 30 7.3 to 8.3 ppm : u.c. : 7 H
 - 8.8 ppm : bs : 1 H
 - 10 to 13 ppm : 2bs : 2 H

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound of formula:



5

in which:

- R represents a group chosen from:

-CN, -C(NH₂)=N-OH, -C(NR₄R₅)=NR₆,

-CONR₁R₂, -CON(R₇)(CH₂)_pNR₁R₂,

-CON(R₇)(CH₂)_qCN, -CON(R₇)(CH₂)_qC(NR₁₄R₁₅)=N-R₁₆,

-CH₂CN, -CH₂CONR₁R₂, -CH₂CON(R₇)(CH₂)_pNR₁R₂,

-CH₂CON(R₇)(CH₂)_qCN, -CH₂COOR₇,

-O(CH₂)_nNR₁R₂, -O(CH₂)_nCONR₁R₂,

-O(CH₂)_nCOOR₇, -O(CH₂)_nSO₂NR₁R₂,

-N(R₇)COR₃, -N(R₇)CO(CH₂)_nNR₁R₂,

-N(R₇)CO(CH₂)_nNHCOR₃, -N(R₇)SO₂R₈,




-N(R₇)CONR₉R₁₀, -CH₂N(R₇)COR₃,

10


-CH₂N(R₇)SO₂R₈, -CH₂CH₂NR₁₁R₁₂,

-CH₂CH₂N(R₇)COR₃, -CH₂CH₂N(R₇)SO₂R₈,

-SO₂NR₁R₂, -SO₂N(R₇)(CH₂)_nNR₁R₂,



- or alternatively R, linked with the carbon atom at position 5 of the naphthyl radical, forms a group:



- p = 2 to 6;

- n = 1 to 6;

- q = 1 to 5;

15 - R₁ and R₂ each independently represent a hydrogen or a (C₁-C₄) alkyl; or R₁ and R₂, together with the nitrogen atom to which they are attached, represent a heterocycle chosen from: pyrrolidine, piperidine, piperazine substituted at position 4 with R₇, morpholine or thiomorpholine;

20 - R₃ represents hydrogen; a (C₁-C₈) alkyl; a (C₃-C₈) cycloalkyl; a phenyl; a piperidyl;
- R₄ and R₅ each independently represent a hydrogen or a (C₁-C₄) alkyl;

25 - R₆ represents a (C₁-C₄) alkyl;
- R₇ represents a hydrogen or a (C₁-C₄) alkyl;
- R₈ represents a (C₁-C₄) alkyl;
- R₉ and R₁₀ each independently represent a hydrogen or a (C₁-C₄) alkyl; R₁₀ can, furthermore, represent a group

30 $-(\text{CH}_2)_n\text{NR}_1\text{R}_2$;
- or R₉ and R₁₀, together with the nitrogen atom to which they are attached, represent a heterocycle chosen from: pyrrolidine, piperidine, piperazine substituted at position 4 with R₇, morpholine or thiomorpholine;

35 - R₁₁ and R₁₂ each independently represent a hydrogen or a (C₁-C₄) alkyl; or R₁₁ and R₁₂, together with the nitrogen atom to which they are attached, represent pyrrolidine or piperidine;

- R₁₃ represents a hydrogen; a group $-(\text{CH}_2)_n\text{NR}_1\text{R}_2$; a group

-NHCOR₃;

- R₁₄ and R₁₅ each independently represent a hydrogen or a (C₁-C₄) alkyl;


- R₁₆ represents a hydrogen; R₁₆ can, furthermore, represent a (C₁-C₄) alkyl when R₁₄ represents a hydrogen and R₁₅ represents a (C₁-C₄) alkyl;

- or R₁₄ and R₁₆ together represent an ethylene group or a trimethylene group and R₁₅ represents a hydrogen or a (C₁-C₄) alkyl;

- T represents hydrogen; a (C₁-C₄) alkyl; an allyl; a (C₃-C₈) cycloalkyl; a (C₃-C₈) cycloalkylmethyl; a methoxyethyl;

- the group -NH-AA(OH) represents the residue of an amino acid:

15



where X is hydrogen and X' is hydrogen, a (C₁-C₅) alkyl or a non-aromatic C₃-C₁₅ carbocyclic radical; or alternatively X and X', together with the carbon atom to which they are attached, form a non-aromatic C₃-C₁₅ carbocycle; and its salts.


2. A compound according to Claim 1 of formula I, in which:

- R represents an aminocarbonyl; aminocarbonylmethyl; acetamido; N-[3-(N',N'-dimethylamino)propyl]aminosulphonyl; N-methyl-N-[3-(N',N'-dimethylamino)propyl]aminosulphonyl; carbamoylmethyloxy; N-[3-(N',N'-dimethylamino)propyl]aminocarbonyl; N-[2-(N',N'-dimethylamino)ethyl]aminocarbonyl; N-methyl-N-[3-(N',N'-dimethylamino)propyl]aminocarbonyl; N-methyl-N-[2-(N',N'-dimethylamino)ethyl]aminocarbonyl group; N-methyl-N-[2-N¹-methyl-N²-methylamidino)ethyl]carbamoyl;

- T represents a methyl or cyclopropylmethyl group; and
- the group -NH-AA-(OH) represents the residue of 2-amino-2-adamantanecarboxylic or (S)-α-aminocyclohexaneacetic

acid;
and its salts.

3. A compound of formula:



5

in which


- R_a represents an N-[3-(N',N'-dimethylamino)propyl]-aminocarbonyl or N-[2-(N',N'-dimethylamino)ethyl]amino-carbonyl group;
and its salts.

10

4. A process for the preparation of a compound according to Claim 1 of formula I and its salts, characterized in that:

15


1) a functional derivative of a 1-naphthyl-3-pyrazolecarboxylic acid of formula:



20 in which T and R have the meanings given above for the compound of formula I and R' represents a precursor of R chosen from nitro, amino, hydroxyl, sulfo, chloro-

ABSTRACT OF THE DISCLOSURE

The invention relates to substituted 1-naphyl-3-pyrazolecarboxamides of formula I :



Application :


These compounds are useful for the treatment of neuropsychiatric disorders, especially those associated with a dysfunction of the dopaminergic systems.

sulphonyl and carboxyl groups, is treated with an amino acid, optionally protected by protective groups which are customary in peptide synthesis, of formula:



in which $-\text{NH}-\text{AA}(\text{OH})$ is as defined above for the compound of formula I;

2) where appropriate, the compound thereby
10 obtained, of formula:





15 is subjected to a subsequent treatment suitable for converting the substituent R' , a precursor of R , to the substituent R ;

3) if necessary, the compound thereby obtained in step 1) or in step 2) is deprotected to yield the corresponding free acid of formula I;

20 4) where appropriate, a salt is prepared of the compound I thereby obtained.

5. Acid of formula:



25


in which T and R have the definitions given in Claim 1 for

the compounds I and R' represents a precursor of R chosen from nitro, amino, hydroxyl, sulpho and chlorosulphonyl groups, as well as the functional derivatives of the acid function.

- 5 6. Compound according to Claim 5, in which the functional derivative of the acid is the acid chloride, the C₁-C₄ alkyl ester or the mixed anhydride with isobutyl or ethyl chloroformate.

7. Compound of formula :

10



15

in which :

- 20 - R_y represents a cyano or carboxymethyl group and its salts.

8. Pharmaceutical composition containing as active principle a compound of formula I according to any one of Claims 1 to 3 or one of its possible pharmaceutically acceptable salts.

- 25 9. Pharmaceutical composition according to Claim 8, in the form of a dosage unit.

10. Pharmaceutical composition according to Claim 9, characterized in that it contains from 0.5 to 250 mg of active principle, mixed with at least one pharmaceutical
30 excipient.

11. A compound according to claim 1, a process for the preparation thereof, or a pharmaceutical composition comprising a said compound, substantially as hereinbefore described with reference to the Examples.

12. The steps, features, compositions and compounds disclosed herein or referred to or indicated in the specification and/or claims of this application, individually or collectively, and any and all combinations of any two or more of said steps or features.

DATED this TWELFTH day of OCTOBER 1994

Sanofi

by DAVIES COLLISON CAVE
Patent Attorneys for the applicant(s)